View Filing Data

Document And Entity Information - shares	6 Months Ended
Document And Entity Information - shares	Jun. 30, 2013	Aug. 09, 2013
Document Information [Line Items]
Entity Registrant Name	ATOSSA GENETICS INC
Entity Central Index Key	0001488039
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Trading Symbol	ATOS
Entity Common Stock, Shares Outstanding		15,580,074
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2013
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2013

CONSOLIDATED BALANCE SHEETS - USD ($)	Jun. 30, 2013	Dec. 31, 2012
Assets
Cash and cash equivalents	$ 2,439,512	$ 1,725,197
Accounts receivable	520,424	141,665
Prepaid expense	2,347,701	122,633
Retainers (deposits)	47,500	0
Total Current Assets	5,355,137	1,989,495
Fixed Assets
Furniture and Equipment, net	205,800	159,967
Total Fixed Assets	205,800	159,967
Other Assets
Security deposit	36,446	36,447
Intangible assets, net	4,457,619	4,640,224
Total Other Assets	4,494,065	4,676,671
Total Assets	10,055,002	6,826,133
Liabilities and Stockholders' Equity
Accounts payable	184,002	68,217
Accrued expenses	1,289,104	1,374,385
Deferred rent	72,537	0
Payroll Liabilities	196,873	207,996
Other current liabilities	31,654
Total Current Liabilities	1,774,170	1,650,598
Stockholders' Equity
Preferred stock - $.001 par value; 10,000,000 shares authorized, 0 shares issued and outstanding	0	0
Common stock - $.001 par value; 75,000,000 shares authorized, 15,338,074 and 12,919,367 shares issued and outstanding	15,338	12,919
Additional paid-in capital	22,522,539	14,894,522
Accumulated deficit	(14,257,045)	(9,731,906)
Total Stockholders' Equity	8,280,832	5,175,535
Total Liabilities and Stockholders' Equity	$ 10,055,002	$ 6,826,133

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Jun. 30, 2013	Dec. 31, 2012
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, authorized	75,000,000	75,000,000
Common stock, shares issued	15,338,074	12,919,367
Common stock, shares outstanding	15,338,074	12,919,367

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended		6 Months Ended		50 Months Ended
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013
Revenue
Diagnostic Testing Service	$ 120,488	$ 219,972	$ 289,718	$ 272,685	$ 765,120
Product Sales	205,590	3,125	219,030	5,125	226,970
Total Revenue	326,078	223,097	508,748	277,810	992,090
Cost of Revenue
Diagnostic Testing Service	2,356	17,788	49,955	20,985	85,700
Product Sales	219,804	0	238,669	0	243,833
Total Cost of Revenue	222,160	17,788	288,624	20,985	329,533
Loss on Reduction of Inventory to LCM	0	0	0	23,807	121,910
Gross Profit	103,918	205,309	220,124	233,018	540,647
Selling expenses	319,390	123,832	591,965	194,267	1,231,841
Research and Development expenses	189,955	543,081	410,147	961,071	3,967,533
General and Administrative expenses	2,177,920	704,208	3,742,792	1,305,660	9,565,126
Total operating expenses	2,687,265	1,371,121	4,744,904	2,460,998	14,764,500
Operating Loss	(2,583,347)	(1,165,812)	(4,524,780)	(2,227,980)	(14,223,853)
Interest Income	0	310	0	1,173	6,588
Interest Expense	352	2,446	359	4,060	39,530
Net Loss before Income Taxes	(2,583,699)	(1,167,948)	(4,525,139)	(2,230,867)	(14,256,795)
Income Taxes	0	0	0	0	250
Net Loss	$ (2,583,699)	$ (1,167,948)	$ (4,525,139)	$ (2,230,867)	$ (14,257,045)
Loss per common share - basic and diluted (in dollars per share)	$ (0.17)	$ (0.10)	$ (0.32)	$ (0.20)	$ (1.63)
Weighted average shares outstanding, basic & diluted (in shares)	14,808,728	11,256,867	14,120,962	11,256,867	8,722,843

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	6 Months Ended		50 Months Ended
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (4,525,139)	$ (2,230,867)	$ (14,257,045)
Common shares issued for services	181,798	0	252,798
Compensation cost for stock options granted	1,011,820	70,662	1,304,084
Loss on reduction of inventory to LCM	20,323	23,807	142,233
Loan initiation fee accrued for notes payable	0	0	2,000
Depreciation and amortization	226,643	17,057	372,818
Adjustments to reconcile net loss to net cash provided by operating activities:
Increase in accounts receivable	(378,759)	(177,055)	(520,424)
Increase in inventory	(20,323)	(23,807)	(142,233)
Increase in prepaid expenses	(36,526)	(149,956)	(159,159)
Increase in security deposits	(47,500)	(32,789)	(83,948)
Increase in accounts payable	115,785	6,702	184,002
Decrease in accrued payroll	(11,123)	0	(11,123)
Increase in deferred rent	72,537	0	72,537
Decrease (Increase) in accrued Expenses	(85,280)	679,600	1,542,101
Increase in Other Current Liabilities	31,654	0	31,654
Net cash used in operating activities	(3,444,090)	(1,816,646)	(11,269,705)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of furniture & fixtures	(81,370)	0	(272,417)
Purchase of Software	(8,500)	0	(88,966)
Net cash used in investing activities	(89,870)	0	(361,383)
CASH FLOWS FROM FINANCING ACTIVITIES
Net proceeds from issuance of common stocks and warrants	4,248,275	0	14,072,601
(Repayments of) proceeds from bank line of credit	0	(750,000)	0
Repayments of loans from related parties	0	(6,178)	(2,000)
Cash released from (restricted for) commercial line of credit	0	750,000	0
Net cash provided by financing activities	4,248,275	(6,178)	14,070,601
NET INCREASE (DECREASE) IN CASH & CASH EQUIVALENTS	714,315	(1,822,824)	2,439,513
CASH & CASH EQUIVALENTS, BEGINNING BALANCE	1,725,197	1,910,821	0
CASH & CASH EQUIVALENTS, ENDING BALANCE	2,439,512	87,997	2,439,512
SUPPLEMENTAL DISCLOSURES:
Interest paid	359	6,036	33,066
Income taxes paid	0	0	250
NONCASH INVESTING AND FINANCING ACTIVITIES:
Common stock and warrants issued for asset purchase	0	0	4,674,853
Options issued for previously accrued director compensation	0	0	45,000
Commitment Shares distributed for Capital contribution	2,387,250	0	2,387,250
Amortization of commitment shares issued for distributed shares	$ 198,958	$ 0	$ 198,958

NATURE OF OPERATIONS	6 Months Ended
NATURE OF OPERATIONS	Jun. 30, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Operations [Text Block]	NOTE 1: NATURE OF OPERATIONS The Company’s operations began in December 2008 with the negotiations for the acquisition of the Mammary Aspirate Specimen Cytology Test System, or the MASCT System, patent rights and assignments and the FDA clearances for marketing, which acquisition was completed in January 2009. Atossa Genetics Inc. (the “Company”) was incorporated on April 30, 2009 in the State of Delaware. The Company was formed to develop and market the MASCT System, a cellular and molecular diagnostic risk assessment product for the detection of pre-cancerous changes that could lead to breast cancer. The Company’s fiscal year ends on December 31st. In December 2011 the Company established the National Reference Laboratory for Breast Health, or NRLBH, as a wholly-owned subsidiary. NRLBH is the Company’s CLIA-certified laboratory where the ForeCYTE and ArgusCYTE test specimens are examined for the presence of normal, pre-malignant, or malignant changes as determined by cytopathology and biomarkers . These test results provide patients and physicians with information about the care path that should be followed, depending on the individual risk of future cancer as determined by the results. In September 2012, the Company acquired the assets of Acueity Healthcare, Inc. (“Acueity”). The purchased assets included 35 issued patents (18 issued in the U.S. and 17 issued in foreign countries) and 41 patent applications (32 in the U.S. and 9 in foreign countries), six 510(k) FDA marketing authorizations related to the manufacturing, use, and sale of the Viaduct Miniscope and accessories, the Manoa Breast Biopsy system, the Excisor Bioptome, the Acueity Medical Light Source, the Viaduct Microendoscope and accessories, and cash in the amount of $400,000. The microendoscopes are less than 0.9 mm outside diameter and can be inserted into a milk duct. This permits a physician to pass a microendoscope into the milk duct system of the breast and view the duct system via fiberoptic video images. Abnormalities that are visualized can then be biopsied from inside the duct with the biopsy tools that are inserted adjacent to the microendoscope. The patents relate to intraductal diagnostic and therapeutic devices and methods of use. The Company did not, however, acquire an inventory of these diagnostic tools, manufacturing capabilities or any personnel to market and sell the tools. The Company cannot provide any assurance that it will be successful commercializing these tools. Development Stage Risk From April 30, 2009 (inception) through June 30, 2013, the Company earned $992,090 in revenue from the sale of its products and laboratory services. The Company’s activities have been accounted for as those of a “Development Stage Enterprise” as set forth in Accounting Standards Codification (“ASC”) 915 “Development Stage Entities”, which was previously Statement of Financial Accounting Standards No. 7 (“SFAS 7”). Among the disclosures required by ASC 915 are that the Company’s financial statements be identified as those of a development stage company, and that the statements of operations, stockholders’ equity and cash flows disclose activity since the date of the Company’s inception. Since its inception, the Company has been dependent upon the receipt of capital investment to fund its continuing activities. In addition to the normal risks associated with a new business venture, there can be no assurance that the Company’s business plan will be successfully executed. The Company’s ability to execute its business plan will depend on its ability to obtain additional financing and achieve a profitable level of operations. There can be no assurance that sufficient financing will be obtained. Further, the Company cannot give any assurance that it will generate substantial revenue or that its business operations will prove to be profitable.

GOING CONCERN	6 Months Ended
GOING CONCERN	Jun. 30, 2013
Going Concern Disclosure [Abstract]
Going Concern Disclosure [Text Block]	NOTE 2: GOING CONCERN The Company’s consolidated financial statements are prepared using generally accepted accounting principles in the United States of America applicable to a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has not yet established an ongoing source of revenue sufficient to cover its operating costs and allow it to continue as a going concern. The ability of the Company to continue as a going concern is dependent on the Company obtaining adequate capital to fund operating losses until it becomes profitable. If the Company is unable to obtain adequate capital, it could be forced to cease operations. The accompanying consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. Management’s Plan to Continue as a Going Concern In order to continue as a going concern, the Company will need, among other things, additional capital resources. Management’s plans to obtain such resources for the Company include (1) obtaining capital from the sale of its equity securities, (2) sales of the MASCT System and laboratory service revenue, and (3) short-term or long-term borrowings from banks, stockholders or other party(ies) when needed. However, management cannot provide any assurance that the Company will be successful in accomplishing any of its plans. The ability of the Company to continue as a going concern is dependent upon its ability to successfully accomplish the plans described in the preceding paragraph and eventually to secure other sources of financing and attain profitable operations.

SUMMARY OF ACCOUNTING POLICIES

6 Months Ended

Jun. 30, 2013

Accounting Policies [Abstract]

Significant Accounting Policies [Text Block]

NOTE 3: SUMMARY OF ACCOUNTING POLICIES

Basis of Presentation:

The accompanying consolidated financial statements include the financial statements of Atossa Genetics Inc. and its wholly-owned subsidiary NRLBH. All significant intercompany account balances and transactions have been eliminated in consolidation. These consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America.

Recently Issued Accounting Pronouncements:

The Company has adopted all recently issued accounting pronouncements that management believes to be applicable to the Company. The adoption of these accounting pronouncements, including those not yet effective, is not anticipated to have a material effect on the financial position or results of operations of the Company.

Revenue Recognition:

Overview

The Company recognizes product and service revenue in accordance with GAAP when the following overall fundamental criteria are met: (i) persuasive evidence of an arrangement exists, (ii) delivery has occurred or the service has been performed, (iii) the Company’s price to the customer is fixed or determinable and (iv) collection of the resulting accounts receivable is reasonably assured.

Product Revenue

The Company recognizes revenue for sales of the MASCT kits and devices on an accrual basis for sales to distributors when the above four criteria are met. For sales of MASCT kits and devices directly to physicians, the revenue is typically recognized upon receipt of cash as the Company has an insufficient sales history on which to determine the collectability. Shipping documents and the completion of any customer acceptance requirements, when applicable, will be used to verify product delivery. The Company will assess whether a price is fixed or determinable based upon the payment terms associated with the transaction and whether the sales price is subject to refund or adjustment. For sales directly to physicians, once a history of sales and collectability has been established, the Company will recognize revenue on an accrual basis with an offsetting reserve for doubtful accounts based on the history during the initial sales period.

Service Revenue

The Company records revenue for diagnostic testing on an accrual basis at the Medicare allowed and invoiced amount. Amounts invoiced above the Medicare amount, namely non-Medicare, are not recognized on an accrual basis and instead are recognized on a cash basis as received. Diagnostic testing revenue at the Medicare rate is recognized upon completion of the test, communication of results to the patient’s physician, and when collectability is reasonably assured. Customer purchase orders and/or contracts will generally be used to determine the existence of an arrangement. Once the Company has historical sales and can determine the proper amount to recognize as uncollectible, it will then begin to recognize the entire amount, both Medicare and non-Medicare billing on an accrual basis, with an offsetting allowance for doubtful accounts recorded based on history. The Company estimates it will utilize the diagnostic testing revenue history once it reaches 12 months of collection data to determine a proper allowance for doubtful accounts.

Cash and Cash Equivalents:

Cash and cash equivalents include cash and all highly liquid instruments with original maturities of three months or less.

Use of Estimates:

The preparation of consolidated financial statements in conformity with generally accepted accounting principles in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Accordingly, actual results could differ from those estimates.

Accounts Receivable:

Accounts receivable are recorded at net realizable value consisting of the carrying amount less allowance for doubtful accounts, as needed. We assess the collectability of accounts receivable based primarily upon the creditworthiness of the customer as determined by credit checks and analysis, as well as the customer’s payment history. Management reviews the composition of accounts receivable and analyzes historical bad debts, customer concentrations, customer credit worthiness, current economic trends, and changes in customer payment patterns to evaluate the adequacy of these reserves. As of June 30, 2013 and December 31, 2012, no allowance for doubtful accounts was assessed or recorded.

Inventories:

The Company’s inventories are stated at lower of cost or market. Cost is determined on a moving-average basis. Costs of inventories include purchase and related costs incurred in delivering the products to their present location and condition. Market value is determined by reference to selling prices after the balance sheet date or to management’s estimates based on prevailing market conditions. Inherent in the lower of cost or market calculation are several significant judgments based on a review of the aging of the inventory, inventory movement of products, economic conditions, and replacement costs. Because the sales price of the MASCT System was substantially lower than its cost for the period ended June 30, 2013 and December 31, 2012, resulting in the net realizable value of the MASCT System being determined at zero as of June 30, 2013 and December 31, 2012, through taking the average sales price subtracted by selling expenses per unit. The Company assessed and recorded $0 and $29,884 loss on reduction of inventory to the lower of cost or market for the six months ended June 30, 2013 and for the year ended December 31, 2012, respectively. Additionally, management periodically evaluates the composition of its inventories at least quarterly to identify slow-moving and obsolete inventories to determine if any valuation allowance is required. As of June 30, 2013 and December 31, 2012, management had identified no slow moving or obsolete inventory.

The Company provides, either directly or through distributors, the ForeCYTE testing specimen collection kits to doctors with our MASCT System for doctors to collect specimens that are returned to the NRLBH for diagnostic analysis. These collection kits are considered part of the MASCT System. During the initial marketing phase in 2012, the Company distributed the kits to customers at no cost and bundled them with the MASCT System, and has not intended to deem the kits as a primary product line due to their nominal cost and value per unit. As a result, the kits are immediately expensed and recorded as selling expense upon purchasing of the kits. In 2013, the Company continues the practice of providing the MASCT System directly to certain physicians free of charge, or by offering a rebate to physicians; however, the MASCT System is not provided free of charge to distributors.

Property, plant, and equipment:

Property, plant and equipment are stated at cost less accumulated depreciation. Expenditures for maintenance and repairs are charged to earnings as incurred; additions, renewals and betterments are capitalized. When property, plant and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations.

Depreciation is computed using the straight-line method over the estimated useful lives of the assets as follows:

	Useful Life (in years)
Machinery and equipment		5
Leasehold improvements		2.083

Intangible assets:

Intangible assets consist of intellectual property and software acquired in the Acueity asset purchase. At least annually, we evaluate purchased intangibles for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition are less than its carrying amount. Estimating future cash flows related to an intangible asset involves significant estimates and assumptions. If our assumptions are not correct, there could be an impairment loss or, in the case of a change in the estimated useful life of the asset, a change in amortization expense. There was no impairment of intangible assets as of and for the six months ended June 30, 2013 and year ended December 31, 2012, respectively.

Amortization is computed using the straight-line method over the estimated useful lives of the assets as follows:

	Useful Life (in years)
Patents		9-14
Software		3

Research and Development Expenses:

Research and development costs are generally expensed as incurred. The Company’s research and development expenses consist of costs incurred for internal and external research and development.

Share Based Payments:

In December 2004, the Financial Accounting Standards Board, or the FASB, issued the Statement of Financial Accounting Standards, or SFAS, No. 123(R), “Share-Based Payment”, which replaces SFAS No. 123 and supersedes APB Opinion No. 25. SFAS No. 123(R) is now included in the FASB’s ASC Topic 718, “Compensation – Stock Compensation.” Under SFAS No. 123(R), companies are required to measure the compensation costs of share-based compensation arrangements based on the grant-date fair value and recognize the costs in the financial statements over the period during which employees or independent contractors are required to provide services. Share-based compensation arrangements include stock options and warrants, restricted share plans, performance-based awards, share appreciation rights and employee share purchase plans. In March 2005, the SEC issued Staff Accounting Bulletin No. 107, or SAB 107, which expresses views of the staff regarding the interaction between SFAS No. 123(R) and certain SEC rules and regulations and provides the staff’s views regarding the valuation of share-based payment arrangements for public companies. SFAS No. 123(R) permits public companies to adopt its requirements using one of two methods. On April 14, 2005, the SEC adopted a new rule amending the compliance dates for SFAS No. 123(R). Companies may elect to apply this statement either prospectively, or on a modified version of retrospective application under which financial statements for prior periods are adjusted on a basis consistent with the pro forma disclosures required for those periods under SFAS No. 123.

The Company has fully adopted the provisions of FASB ASC 718 and related interpretations as provided by SAB 107. As such, compensation cost is measured on the date of grant as the fair value of the share-based payments. Such compensation amounts, if any, are amortized over the respective vesting periods of the option grant.

PREPAID EXPENSES

6 Months Ended

Jun. 30, 2013

Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]

Prepaid Expenses [Text Block]

NOTE 4: PREPAID EXPENSES

Prepaid expenses consisted of the following:

	June 30, 2013		December 31, 2012
Prepaid Stock Purchase Agreement Service Fee	$	2,188,542	$	-
Prepaid Insurance		52,864		62,551
Prepaid Hardware/Software Maintenance and Support Service Fee		37,867		20,000
Prepaid Payroll Taxes		35,950		40,082
Prepaid Rent		25,629
Prepaid Tradeshow		6,849		-
	$	2,347,701	$	122,633

PROPERTY, PLANT, AND EQUIPMENT

6 Months Ended

Jun. 30, 2013

Property, Plant and Equipment [Abstract]

Property, Plant and Equipment Disclosure [Text Block]

NOTE 5: PROPERTY, PLANT, AND EQUIPMENT

Property, plant and equipment consisted of the following:

	June 30, 2013		December 31, 2012
Machinery and equipment	$	178,752	$	97,383
Leasehold Improvements		93,665		93,665
Less: Accumulated depreciation		(66,617)		(31,081)
Property, plant, and equipment, net	$	205,800	$	159,967

Depreciation expense for the six months ended June 30, 2013 and2012 was $35,537 and $8,647, respectively.

INTANGIBLE ASSETS

6 Months Ended

Jun. 30, 2013

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill and Intangible Assets Disclosure [Text Block]

NOTE 6: INTANGIBLE ASSETS

Intangible assets consisted of the following:

	June 30,		December 31,
	2013		2012
Patents	$	4,704,853	$	4,704,853
Software		58,966		50,466
Less: Accumulated amortization		(306,200)		(115,095)
	$	4,457,619	$	4,640,224

Intangible assets amounted to $4,457,619 and $4,640,224 as of June 30, 2013 and December 31, 2012 respectively, mainly consisted of patents and software acquired. The acquired software in the amount of $50,466 and $58,966 as of June 30, 2013 and December 31, 2012, respectively, is for the purpose of managing laboratory results pursuant to a software installation agreement that was entered into on June 8, 2011. The amortization period for the purchased software is 3 years. Amortization expense related to software for the six months ended June 30, 2013 and 2012 was $9,591 and $8,410, respectively.

Patents amounted to $4,704,853 and $4,704,853 as of June 30, 2013 and December 31, 2012, respectively, and mainly consisted of patents acquired from Acueity on September 30, 2012 in an asset purchase transaction (see Note 13). Patent assets will be amortized based on their determined useful life, and tested annually for impairment. The amortization period was from 9 to 14 years. Amortization expense related to patents was $181,514 and $0 for the six months ended June 30, 2013 and 2012, respectively.

Future estimated amortization expenses as of June 30, 2013 for the five succeeding years is as follows:

As of June 30,	Amounts
2013	$	382,683
2014		366,022
2015		364,681
2016		363,028
2017		363,028
Thereafter		2,618,177
	$	4,457,619

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References + Details

ACCRUED EXPENSES

6 Months Ended

Jun. 30, 2013

Payables and Accruals [Abstract]

Accounts Payable and Accrued Liabilities Disclosure [Text Block]

NOTE 7: ACCRUED EXPENSES

Accrued expenses consisted of the following:

	June 30,		December 31,
	2013		2012
Accrued expenses	$	1,289,104	$	1,374,385
Accrued bonus payable		169,375		189,131
Accrued payroll tax liabilities		27,498		18,866
Deferred Rent		72,537		-
	$	1,558,514	$	1,582,382

STOCKHOLDERS' EQUITY

6 Months Ended

Jun. 30, 2013

Stockholders' Equity Note [Abstract]

Stockholders' Equity Note Disclosure [Text Block]

NOTE 8: STOCKHOLDERS’ EQUITY

The Company is authorized to issue a total of 85,000,000 shares of stock consisting of 75,000,000 shares of Common Stock, par value $0.001 per share, and 10,000,000 shares of Preferred Stock, par value $0.001 per share.

Reverse Stock-Split

On September 28, 2010, the Board of Directors approved a 1-for-2.26332 reverse share split for all issued and outstanding shares of Common Stock, with no change to the par value of the Common Stock.

Prior Issuances of Common Stock

On April 30, 2009 (inception), the Company issued 1,767,316 shares (or 4,000,000 shares prior to the reverse stock-split on September 28, 2010) to Ensisheim Partners LLC, a related party to the Company through common ownership, for cash in the amount of $24,000, or $0.014 per share (or $0.006 per share prior to the reverse stock-split on September 28, 2010); 1,325,487 shares (or 3,000,000 shares prior to the reverse stock-split on September 28, 2010) to Manistee Ventures LLC, a related party to the Company through common ownership, for cash in the amount of $18,000, or $0.014 per share (or $0.006 per share prior to the reverse stock-split on September 28, 2010); and 883,662 shares (or 2,000,000 shares prior to the reverse stock-split on September 28, 2010) to the Chairman, CEO and President of the Company at that time for cash in the amount of $12,000, or $0.014 per share (or $0.006 per share prior to the reverse stock-split on September 28, 2010).

On July 28, 2009, the Company issued 39,765 shares (or 90,000 shares prior to the reverse stock-split on September 28, 2010) to a director of the Company for cash in the amount of $540, or $0.014 per share (or $0.006 per share prior to the reverse stock-split on September 28, 2010).

On December 28, 2009, the Company issued 883,658 shares (or 2,000,000 shares prior to the reverse stock-split on September 28, 2010) to Ensisheim Partners LLC for cash in the amount of $100,000, or $0.11 per share (or $0.05 per share prior to the reverse stock-split on September 28, 2010).

On January 21, 2010, the Company issued 866,007 shares (or 1,960,000 shares prior to the reverse stock-split on September 28, 2010) to forty-four (44) investors for cash in the amount of $98,000, or $0.11 per share (or $0.05 per share prior to the reverse stock-split on September 28, 2010).

On January 21, 2010, the Company issued 132,549 shares (or 300,000 shares prior to the reverse stock-split on September 28, 2010) to a service provider for effecting transactions intended to cause the Company to become a public company and to have its securities traded in the United States. The shares were issued at a value of $15,000, or $0.11 per share (or $0.05 per share prior to the reverse stock-split on September 28, 2010), the same price as the issuance of the 866,007 shares (or 1,960,000 shares prior to the reverse stock-split on September 28, 2010) for cash on the same date.

On January 21, 2010, the Company issued an additional 53,020 shares (or 120,000 shares prior to the reverse stock-split on September 28, 2010) to a shareholder who acquired 13,255 shares (or 30,000 shares prior to the reverse stock-split on September 28, 2010) for cash on the same date as one of the forty-four (44) investors. Those shares were issued to the shareholder for services to be performed, including investor relations, media relations, and corporate communications. Those shares were issued at a value of $6,000, or $0.11 per share (or $0.05 per share prior to the reverse stock-split on September 28, 2010), the same price as the issuance of the 866,007 shares (or 1,960,000 shares prior to the reverse stock-split on September 28, 2010) for cash on the same date.

On January 23, 2010, the Company issued 35,346 shares (or 80,000 shares prior to the reverse stock-split on September 28, 2010) to an investor for cash in the amount of $4,000, or $0.11 per share (or $0.05 per share prior to the reverse stock-split on September 28, 2010).

On April 27, 2010, the Company issued 13,256 shares (or 30,000 shares prior to the reverse stock-split on September 28, 2010) to a service provider for website development services pursuant to an original agreement between the Company and the website developer executed on December 14, 2009 (the “measurement date”), where it was agreed at that time that, at the Company’s option, $50,000 would be paid or 13,256 shares (or 30,000 shares of common stock prior to the reverse stock-split on September 28, 2010) would be issued to the developer in exchange for his services.

On September 30, 2012, the Company issued 862,500 shares to the shareholders of Acueity as part of the consideration for the asset purchase (see Note 13). The shares were valued at $5.00 per share, the offering price of the then contemplated initial public offering, for which the registration statement on Form S-1 (File No. 333-179500) was subsequently declared effective by the Securities and Exchange Commission on November 7, 2012, and a prospectus was subsequently filed pursuant to Rule 424(b)(4) on November 9, 2012 (see Note 14), or $4,312,500 in total.

On November 7, 2012, the Company’s registration statement on Form S-1 (File No. 333-179500) was declared effective by the Securities and Exchange Commission for the Company’s initial public offering. On November 9, 2012, pursuant to Rule 424(b)(4), the Company filed a prospectus for the initial public offering of 800,000 shares of its common stock with the offering price of $5.00 per share. As a result of the initial public offering, the Company received net proceeds of $3,454,000 after deducting underwriting discounts and commissions of approximately $546,000.

On January 24, 2013, the Company issued 32,186 shares of Common Stock to consultants as compensation for the performance of services to the Company. The aggregate value of shares issued was $143,550, or $4.46 per share, the fair market value of the Company’s Common Stock on the date of issuance.

From March 27, 2013 to June 30, 2013, the Company issued 933,333 shares to Aspire Capital Fund, LLC as part of a stock purchase agreement, including 250,000 shares of Common Stock as a commitment fee, resulting in $3,969,740 in gross proceeds to the company. The Company incurred placement agent fees of $119,071 and issued placement agent warrants to purchase 18,000 shares of Common Stock at $5.80 per share, in connection with these stock sales to Aspire.

From January 1, 2013 to June 30, 2013, the Company issued 5,546 shares of common stock to various employees who elected to exercise their incentive stock options at a price of $1.25 per share, resulting in $6,000 in proceeds to the Company

During 2013, the Company issued 1,279,642 shares of Common Stock each upon exercise of outstanding warrants on a cashless basis and 60,000 shares upon exercise of warrants for cash. The non-cash warrants were exercised on a “net” basis without additional consideration received by the Company. These warrants were originally issued in 2011 in connection with the Company’s private placement to accredited investors pursuant to Rule 506 of Regulation D under the Act.

Private Placements and Warrants

On April 28, May 31, June 10, and June 23, 2011, pursuant to Securities Purchase Agreements with various investors (the “Investors”), the Company issued 5,256,800 shares of the Company’s common stock and 5,256,800 warrants (the “Investor Warrants”), each of which entitles the investors to purchase the Company’s common stock at $1.25 per share, for aggregate gross proceeds of $6,571,000 (the “Private Placement”).

Placement Agent Fees

In connection with the Private Placement, the Company paid Dawson James Securities, Inc. (the “Placement Agent”), a cash fee equal to 10% of the gross proceeds from sale of the common stocks and warrants, plus a 3% non-accountable expense allowance, which resulted in a payment to the Placement Agent of an aggregate of $857,230 (the “Placement Agent Fee”). In addition, the Company entered into Warrant Agreements with the Placement Agent pursuant to which the Placement Agent received 788,520 warrants, each of which entitles the Placement Agent to purchase one share of the Company’s common stock at $1.60 per share, plus an additional 788,520 warrants (collectively with the warrants exercisable at $1.60 per share, the “Placement Agent Warrants”), each of which entitles the placement agent to purchase the Company’s common stock at $1.25 per share. The cash payment of the $857,230 Placement Agent Fee and the $495,876 aggregated initial fair value of the Placement Agent Warrants (see Fair Value Considerations below) were directly attributable to an actual offering and were charged through additional paid-in capital in accordance with the SEC Staff Accounting Bulletin (SAB) Topic 5A.

Warrants

The Warrants, including the Investor Warrants and the Placement Agent Warrants, are exercisable at any time commencing after June 23, 2011 which is the date that the Company completed a “significant private financing” under the terms of the Warrants (the “Initial Exercise Date”). The Warrants shall expire and no longer be exercisable on the fifth anniversary of the Initial Exercise Date (the “Expiration Date”). The Warrants may be exercised for cash or, at the option of the holder, may be exercised on a cashless basis; however if a registration statement is in effect for the resale of the common stock issuable upon exercise of the Warrants then the Warrants cannot be exercised on a cashless basis. As of June 30, 2013 such a registration statement was in effect and, therefore, the Warrants cannot be exercised on a cashless basis. As of June 30, 2013, substantially all of the Placement Agents Warrants have been exercised. There are no redemption features embodied in the Warrants and they have met the conditions provided in current accounting standards for equity classification.

Fair Value Considerations

The Company’s accounting for the issuance of warrants to the Investors and the Placement Agent required the estimation of fair values of the financial instruments. The development of fair values of financial instruments requires the selection of appropriate methodologies and the estimation of often subjective assumptions. The Company selected the valuation techniques based upon consideration of the types of assumptions that market participants would likely consider in exchanging the financial instruments in market transactions. The warrants were valued using a Black-Scholes-Merton Valuation Technique because it embodies all of the requisite assumptions (including trading volatility, estimated terms and risk free rates) necessary to fair value these instruments.

The Investor Warrants and the Placement Agent Warrants were initially valued at $1,808,025 or $0.344 per warrant, $228,712 or $0.290 per warrant, and $267,164 or $0.339 per warrant, respectively. The following tables reflect assumptions used to determine the fair value of the Warrants:

	Fair		April-June2011			December 2011
	Value Hierarchy Level		Investor Warrants			Placement Agent Warrants			Placement Agent Warrants

Indexed shares				5,256,800			788,520			788,520
Exercise price			$	1.60		$	1.60		$	1.25

Significant assumptions:
Stock price		3	$	0.906		$	0.906		$	0.906
Remaining term		3		6 years			6 years			6 years
Risk free rate		2		2.49	%		1.12	%		1.12	%
Expected volatility		3		53.55	%		54.21	%		54.21	%

Fair value hierarchy of the above assumptions can be categorized as follows:

(1)

There were no Level 1 inputs.

(2)

Level 2 inputs include:

Risk-free rate- The risk-free rate of return reflects the interest rate for United States Treasury Note with similar time-to-maturity to that of the warrants.

(3)

Level 3 inputs include:

Stock price- The Company’s common stock was not publicly traded at the time the Warrants were issued. Therefore, the stock price was determined implicitly from an iterative process in order for the combined fair value of the common stock and the warrants to equal the amount of proceeds received in the Private Placement, based upon the assumption that the Private Placement was the result of an arm’s length transaction.

Remaining term- The Company does not have a history to develop the expected term for its warrants. Accordingly, the Company expected that the Initial Exercise Date would occur within one year from the date of issuance plus the contractual term in the calculations.

Expected volatility- We did not have a historical trading history sufficient to develop an internal volatility rate for use in the model. As a result, as required by ASC 718-10-30, the Company has accounted for the warrants using the calculated value method. The Company identified seven public entities in the similar industry for which share price information was available, and considered the historical volatilities of those public entities’ share prices in calculating the expected volatility appropriate to the Company.

Asset Purchase and Warrants

On September 30, 2012, pursuant to the asset purchase agreement with Acueity, the Company issued 862,500 shares of common stock and 325,000 warrants (“Acueity Warrants”) to the shareholders of Acueity, each of which entitles the recipients to subscribe for and purchase from the Company one share of the Company’s common stock at $5.00 per share (the “Exercise Price”), subject to a six-month lock up agreement.

Warrants

The Acueity Warrants are exercisable at any time commencing after September 30, 2012 (the “Issuance Date”) and shall expire and no longer be exercisable on the fifth anniversary of the Issuance Date (the “Expiration Date”). The Company may at any time during the term of the Acueity Warrants reduce the then current Exercise Price to any amount and for any period of time deemed appropriate by the Board of Directors of the Company. The Acueity Warrants do not have a cashless exercise provision. There are no redemption features embodied in the Acueity Warrants and they have met the conditions provided in current accounting standards for equity classification.

Fair Value Considerations

The Company’s accounting for the issuance of the Acueity Warrants required the estimation of fair values of the financial instruments. The development of fair values of financial instruments requires the selection of appropriate methodologies and the estimation of often subjective assumptions. The Company selected the valuation techniques based upon consideration of the types of assumptions that market participants would likely consider in exchanging the financial instruments in market transactions. The warrants were valued using a Black-Scholes-Merton Valuation Technique because it embodies all of the requisite assumptions (including trading volatility, estimated terms and risk free rates) necessary to fair value these instruments.

The Acueity Warrants were valued at $762,353 or $2.3457 per warrant. The following tables reflect assumptions used to determine the fair value of the Warrants:

	Fair Value Hierarchy		September 2012
	Level		Acueity Warrants

Indexed shares				325,000
Exercise price			$	5.00

Significant assumptions:
Stock price		3	$	5.00
Remaining term		3		5 years
Risk free rate		2		0.62	%
Expected volatility		3		56.54	%

Fair value hierarchy of the above assumptions can be categorized as follows:

(1)

There were no Level 1 inputs.

(2)

Level 2 inputs include:

Risk-free rate- The risk-free rate of return reflects the interest rate for United States Treasury Note with similar time-to-maturity to that of the warrants.

(3)

Level 3 inputs include:

Stock price- The Company’s common stock was not publicly traded at the time the Acueity Warrants were issued. Therefore, the stock price was determined at the offering price of the then contemplated initial public offering, for which the registration statement on Form S-1 (File No. 333-179500) was subsequently declared effective by the Securities and Exchange Commission on November 7, 2012, and a prospectus was subsequently filed pursuant to Rule 424(b)(4) on November 9, 2012 (see Note 14).

Through June 30, 2013, the Company has granted warrants to purchase 18,000 shares of common stock to the placement agent in connection with the financing facility with Aspire Capital. The warrants are exercisable at $5.80 per share and expire on May 15, 2017. An expense of $26,053 has been recognized in the second quarter of 2013 for issuance of these warrants.

On September 28, 2010, the Board of Directors approved the adoption of the 2010 Stock Option and Incentive Plan, or the 2010 Plan, subject to stockholder approval, to provide for the grant of equity-based awards to employees, officers, non-employee directors and other key persons providing services to the Company. Awards of incentive options may be granted under the 2010 Plan until September 2020. No other awards may be granted under the 2010 Plan after the date that is 10 years from the date of stockholder approval. An aggregate of 1,000,000 shares (or 2,263,320 shares prior to the reverse stock-split on September 28, 2010) were initially reserved for issuance in connection with awards granted under the 2010 Plan, such number of shares to be subject to adjustment as provided in the plan and in any award agreements entered into by the Company under the plan, and upon the exercise or conversion of any awards granted under the plan. On January 1, 2012, 400,000 shares were added to the 2010 Plan and on January 1, 2013, 500,000 shares were added to the 2010 Plan, as provided under the terms of the 2010 Plan.

On September 1, 2011, 219,000 incentive stock options were granted under the 2010 Plan to employees and officers and 200,000 non-qualified stock options were granted under the Plan to non-employee directors, respectively, for their employment with and services to be provided to the Company (see Note 12).

On April 30, 2012, 19,757 non-qualified stock options were granted under the 2010 Plan to members of the Board of Directors for their services provided to the Company.

On December 17, 2012, 228,000 incentive stock options were granted under the 2010 Plan to employees for their employment with and services to be provided to the Company (see Note 12).

On December 20, 2012, 200,000 inducement stock options were granted outside of the 2010 Plan to an employee for his employment with and services to be provided to the Company (see Note 12).

On January 4, 2013, 405,000 non-qualified stock options were granted outside of the 2010 Plan, and 95,000 incentive stock options were granted under the 2010 Plan, to an employee for his employment with and services to be provided to the Company (see Note 12).

On January 5, 2013, 32,000 incentive stock options were granted under the 2010 Plan to employees for their employment with and services to be provided to the Company (see Note 12).

On March 11, 2013, 70,710 non-qualified stock options were granted under the 2010 Plan to employee directors for their employment with and services provided to the Company in 2012 (see Note 12).

On May 6, 2013, 329,944 non-qualified stock options were granted under the 2010 Plan to the Board of directors for their 2012 and 2013 services on the Board and for committee services annual fees. The 2012 options are fully vested and the 2013 will vest over 12 months.

In June 2013, 250,000 stock options, 87,000 of which were under the 2010 Plan and 163,000 of which were non-qualified and granted outside the 2010 Plan, were granted to the Senior Vice President of Operations as an inducement to enter into employment with the Company. 120,000 additional stock options were also granted under the 2010 Plan during the same time to employees as bonuses and employment incentives.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph d
-Article 4

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29, 30, 31
-Article 5

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Article 4

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3

+ Details

INCOME TAXES	6 Months Ended
INCOME TAXES	Jun. 30, 2013
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	NOTE 9: INCOME TAXES The Company accounts for income taxes as outlined in ASC 740, “Income Taxes”, which was previously Statement of Financial Accounting Standards No. 109, “Accounting for Income Taxes” (“SFAS 109”). Under the asset and liability method of SFAS 109, deferred income tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial reporting and tax bases of assets and liabilities and are measured using enacted tax rates in effect for the year in which those temporary differences are expected to be recovered or settled. A valuation allowance is provided for the amount of deferred tax assets that, based on available evidence, are not expected to be realized. As a result of the Company’s cumulative losses, management has concluded that a full valuation allowance against the Company’s net deferred tax assets is appropriate. No income tax liabilities existed as of June 30, 2013 and December 31, 2012 due to the Company’s continuing operating losses.

CONCENTRATION OF CREDIT RISK	6 Months Ended
CONCENTRATION OF CREDIT RISK	Jun. 30, 2013
Risks and Uncertainties [Abstract]
Concentration Risk Disclosure [Text Block]	NOTE 10: CONCENTRATION OF CREDIT RISK Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash deposits. Accounts at each institution are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000. At June 30, 2013 and December 31, 2012, the Company had $2,189,512 and $1,475,197 in excess of the FDIC insured limit, respectively.

COMMITMENTS AND CONTINGENCIES

6 Months Ended

Jun. 30, 2013

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies Disclosure [Text Block]

NOTE 11: COMMITMENTS AND CONTINGENCIES

Lease Commitments

On September 29, 2010, the Company entered into a commercial lease agreement with CompleGen, Inc. for laboratory space located in Seattle, WA. The lease provides for monthly rent of $3,658 and a security deposit of $3,658. The lease terms are from September 29, 2010 through March 31, 2011, at which time the lease has converted to month to month unless two months’ prior written notice of the intent to terminate the agreement is given. The monthly rent for the lease increased to $4,267 commencing January 2012. For the year ended December 31, 2012, the Company incurred $46,529 of rent expense for the lease. The lease was terminated in December 2012, and the rental deposit was applied to the rent of the final month.

On March 4, 2011, the Company entered into a commercial lease agreement with Sanders Properties, LLC for office space located in Seattle, WA. The lease provides for monthly rent of $1,100 and a security deposit of $1,500. The lease terms are from April 1, 2011 through March 31, 2014. For the six months ended June 30, 2013, the Company incurred $6,600 of rent expense for the lease.

On July 9, 2011, the Company entered into a commercial lease agreement with Sanders Properties, LLC for additional office space located in Seattle, WA. The lease provides for monthly rent of $600 and a security deposit of $1,200. The lease terms are from July 11, 2011 through July 31, 2012. For the year ended December 31, 2012, the Company incurred $4,200 of rent expense for the lease. This lease terminated on July 31, 2012 and was not renewed.

On September 27, 2011, the Company entered into another commercial lease agreement with Sanders Properties, LLC for additional office space located in Seattle, WA. The lease provides for monthly rent of $1,400 and a security deposit of $1,000. The lease terms are from October 1, 2011 to March 31, 2012. For the period of October 1, 2011 through March 31, 2012, the Company incurred $8,400 of rent expense for the lease. This lease terminated on March 31, 2012 and was not renewed.

On December 9, 2011, the Company entered into another commercial lease agreement with Fred Hutchinson Research Center for lab and office space located in Seattle, WA. The lease provides for monthly rent of $16,395 for the period from February 24, 2012 to August 31, 2012, $19,923 for the period from September 1, 2012 to August 31, 2013, and $20,548 for the period from September 1, 2013 to November 29, 2014. The security deposit of $32,789 was paid in March 2012 and recorded as Security Deposit on the consolidated balance sheet as of December 31, 2012. For the six months ended June 30, 2013, the Company incurred $132,284 of rent expense for the lease, which included leasing office management expenses.

The future minimum lease payments due subsequent to June 30, 2013 under all non-cancelable operating leases for the next five years are as follows:

As of June 30,	Amount
2014	$	323,969
2015		132,737
2016		-
2017		-
2018		-
Thereafter		-
Total minimum lease payments	$	456,706

Contingencies

On June 30, 2011, Robert Kelly, the Company’s former President, filed a counterclaim against the Company in an arbitration proceeding, alleging breach of contract in connection with the termination of a consulting agreement between Mr. Kelly (dba Pitslayer LLC) and the Company that was entered into in July 2010 in connection with his resignation from the Company as President and a director. The consulting agreement was terminated by the Company in September 2010. Mr. Kelly seeks $450,000 in compensatory damages, which is the amount he claims would have been earned had the consulting agreement been fulfilled to completion.

On December 11, 2012, Mr. Kelly filed a complaint in the United States District Court, Western Division of Washington seeking compensatory damages, interest and attorneys’ fees related to the termination of Mr. Kelly’s consulting contract and the rescission of shares issued to him in July 2010 in connection with his resignation from the Company as President and a director. The specific amount of damages sought is to be proven at trial and is not specified. On July 8, 2013 the court granted the Company’s motion to compel arbitration of these claims and therefore this action was dismissed.

On February 26, 2013, Mr. Victor Cononi filed a complaint in the United States District Court, Western Division of Washington seeking compensatory damages, interest and attorneys’ fees related to the rescission of shares issued to him in July 2010 in connection with Mr. Kelly’s resignation from the Company as President and a director. At the time, Mr. Cononi was the father of Mr. Kelly’s paramour. The specific amount of damages sought is to be proven at trial and is not specified. A motion is pending before the court to compel arbitration of these claims.

A hearing in the arbitration has been postponed pending certain procedures in the above Western Division action and may be delayed further to accommodate other third party civil and federal criminal proceedings alleging securities and wire fraud that have been brought against Mr. Kelly with respect to his prior employment and predating his service with the Company.

The Company is reasonably confident in its defenses to Mr. Kelly’s and Mr. Cononi’s claims. Consequently, no provision or liability has been recorded for these claims as of June 30, 2013. However, it is at least reasonably possible that the Company’s estimate of liability may change in the near term. Any payments by reason of an adverse determination in this matter will be charged to earnings in the period of determination.

FDA Warning Letter

On February 21, 2013, the Company received a Warning Letter (“Letter”) from the FDA regarding its Mammary Aspirate Specimen Cytology Test (MASCT) System and MASCT System Collection Test (together, the “System”). The Letter arises from certain FDA findings during a July 2012 inspection, to which the Company responded in August 2012, explaining why the Company believed it was in compliance with applicable regulations and/or was implementing changes responsive to the findings of the FDA inspection. FDA alleges in the Letter that following 510(k) clearance the Company changed the System in a manner that requires submission of an additional 510(k) notification to the FDA. Specifically, the FDA observes that the Instructions For Use (IFU) in the original 510(k) submission stated that the user must “Wash the collection membrane with fixative solution into the collection vial…” and the current IFU states “…apply one spray of Saccomanno’s Fixative to the collection membrane…” and that “this change fixes the NAF specimen to the filter paper rather than washing it into a collection vial.” At the time that the changes were made the Company determined that a new 510(k) was not required in accordance with the FDA’s guidance document entitled, “Deciding When to Submit a 510(k) for a Change to an Existing Device.” The Letter also raises certain issues with respect to the Company’s marketing of the System and the Company’s compliance with FDA Good Manufacturing Practices (cGMP) regulations, among other matters. The Company responded to the Letter on March 13, 2013.

The Company is reasonably confident in its responses to the FDA. Consequently, no provision or liability has been recorded as of June 30, 2013 as a result of the Letter. However, it is at least reasonably possible that the Company’s estimate of related liability may change in the near term. Any payments by reason of an adverse determination in this matter will be charged to earnings in the period of determination.

RELATED PARTY TRANSACTIONS

6 Months Ended

Jun. 30, 2013

NOTE 12: RELATED PARTY TRANSACTIONS

Loans from Officer

On May 26, 2009, the Company borrowed $5,000 from its Chairman of the Board and Chief Executive Officer as a short-term, unsecured loan via verbal agreement and did not bear any interest. Commencing June 30, 2010, the loan was converted into a written Promissory Note bearing an annual interest rate of 10%, with a maturity date of December 31, 2010. This note was repaid in full on May 16, 2011 including approximately $439 of accrued interest.

On June 30, 2010, the Company borrowed an additional $100,000 from its Chairman of the Board and Chief Executive Officer pursuant to a promissory note. The loan under the note was funded to the Company on July 12, 2010. The note bears a 10% interest rate per annum and carries a $4,000 loan origination fee which is accreted to the loan balance throughout the life of the loan. The $4,000 loan origination fee was fully accreted to the loan balance as of March 31, 2011 and December 31, 2010, and recorded as interest expense for the year ended December 31, 2010. This note (including the $4,000 origination fee) was repaid in full on May 19, 2011 including approximately $8,959 in accrued interest.

On November 3, 2010, the Company entered into a line of credit agreement for borrowing up to $500,000 from its Chairman of the Board and Chief Executive Officer pursuant to a promissory note. The note bears a 10% interest rate per annum. An aggregate of $140,000 was funded to the Company under the line of credit as of March 31, 2011 which was repaid on May 31, 2011, including approximately $6,093 in accrued interest. As of December 31, 2011, the unpaid principal balance drawn from the line of credit was $5,078, which was fully repaid on March 31, 2012.

On July 30, 2012, the Company entered into a line of credit agreement for borrowing up to $500,000 from its Chairman of the Board and Chief Executive Officer pursuant to a promissory note. The note bears a 12% interest rate per annum. An aggregate of $79,300 was funded to the Company under the line of credit as of December 31, 2012. The principal balance of $79,300 and interest of $1,440 was fully repaid on October 11, 2012.

Exclusive License Agreement

On July 27, 2009, the Company entered into an exclusive license agreement with Ensisheim Partners LLC (“Ensisheim”), an entity solely owned by the Chairman and Chief Executive Officer of the Company and the Chief Scientific Officer of the Company, who is also the wife of the Company’s Chairman and CEO. Pursuant to that agreement, Ensisheim granted the Company an exclusive, worldwide, perpetual, irrevocable, royalty-bearing, license to the MASCT System, with the right to grant and authorize sublicenses. The license agreement provided that the Company would pay Ensisheim a royalty equal to 2% of net sales revenue, with a minimum royalty of $12,500 per fiscal quarter during the term of the agreement, which would have increased to a minimum royalty of $25,000 per fiscal quarter beginning in the quarter in which the first commercial sale of a licensed product would have taken place. From inception through December 31, 2010, the Company had incurred $16,250 in patent-related expenses under the license agreement with Ensisheim, and $0 subsequent to December 31, 2010.

On June 17, 2010, the Company and Ensisheim entered into an Assignment Agreement, whereby Ensisheim assigned to the Company all rights to the patents and patent applications underlying the MASCT System. Pursuant to the assignment, the Company will have all responsibility for prosecution, maintenance, and enforcement and will indemnify Ensisheim from any and all claims against the patent estate. Ensisheim retained no residual rights with respect to the patents and patent applications. In conjunction with the assignment, the Company terminated the exclusive license agreement between the Company and Ensisheim dated July 27, 2009. As a result of the termination, the Company has no further obligations with respect to royalty payments to Ensisheim due under the old licensing agreement. As a result, the $12,500 of patent royalty payable to Ensisheim recorded as accrued royalty payable at December 31, 2009 has been reversed through royalty expense during the second quarter of 2010.

Commercial Lease Agreement

On December 24, 2009, the Company entered into a commercial lease agreement with Ensisheim for office space located in Seattle, Washington. The lease provided for annual rent of $13,200, plus applicable sales tax. From inception through December 31, 2009, the Company incurred $248 of rent expense for the lease with security deposit of $1,100. For the period of January 1, 2010 through June 30, 2010, the Company incurred $6,600 of rent expense for the lease. On July 15, 2010 the Company and Ensisheim terminated the lease, effective July 1, 2010 and the Company commenced use of the facility rent free until April 1, 2011 when the commercial lease agreement the Company entered into with Sanders Properties, LLC became effective (see Note 11). The $1,100 security deposit paid to Ensisheim was received as of December 31, 2012.

Executive Compensation

On May 19, 2010, the Company entered into employment agreements with three executives, including its Chief Executive Officer, its former President, and its Chief Scientific Officer. The annual base salaries under each agreement were calculated based on combined consideration of the success of capital raise and the operating results of the Company, and capped at $360,000, $350,000, and $250,000, respectively for the three executives.

On July 22, 2010, in connection with the resignation and departure of Robert L. Kelly, the President and a director, the Company entered into a consulting agreement with a limited liability company controlled by Mr. Kelly. Under the agreement, the Company was to receive consulting services relating to capital raising and investor relations. The agreement was terminated by the Company in September 2010, through which time a total of $30,000 consulting expense had been paid.

On July 22, 2010, the Company restated and amended the employment agreements with its CEO and CSO. The agreements modified the base annual salary amounts to $250,000 and $200,000, respectively, effective retroactively to May 19, 2010. For the year ended December 31, 2011, the total amount of salaries and bonuses of the CEO and CSO was $693,048, of which $492,095 was recorded to research and development expense. For the year ended December 31, 2012, salaries and bonuses of CEO and CSO amounted to $322,590 and $243,554, of which $161,295 and $243,554 were recorded to research and development expense, respectively.

Share-Based Compensation

The amended employment agreement with the CEO, entered into on July 22, 2010, granted options to purchase 250,000 shares (or 565,830 shares prior to the reverse stock-split on September 28, 2010) at a price of $5.00 per share, in consideration of his service to the Company. Of these options, 25% (or 62,500 shares) vested on December 31, 2010 with the remaining 75% (or 187,500 shares) to vest in equal quarterly installments over the next three years so long as the executive remains employed with the company. These options have five-year contractual terms.

The amended employment agreement with the CSO, entered into on July 22, 2010, granted options to purchase 100,000 shares (or 226,332 shares prior to the reverse stock-split on September 28, 2010) at a price of $5.00 per share in consideration of her service to the Company. Of these options, 25% (or 25,000 shares) vested on December 31, 2010 with the remaining 75% (or 75,000 shares) to vest in equal quarterly installments over the next three years so long as the executive remains employed with the company. These options have five-year contractual terms.

On April 4, 2011, 45,000 non-qualified stock options were granted under the 2010 Plan to Dr. Tim Hunkapiller for being a member of the Company’s Scientific Advisory Board and consulting services to be provided to the Company, at an exercise price of $1.25 per share. These options have a ten-year contractual term and shall vest as follows:

(i)

11,250 option shares shall vest ninety (90) days after the date of grant;

(ii)

11,000 option shares shall vest one hundred and eighty (180) days after the date of grant;

(iii)

11,500 option shares shall vest two hundred and seventy (270) days after the date of grant;

(iv)

11,250 option shares shall vest three hundred and sixty (360) days after the date of grant.

On September 1, 2011, 219,000 incentive stock options were granted under the 2010 Plan to employees and officers as part of their employment agreements, at an exercise price of $1.25 per share. These options have a ten-year contractual term and shall vest and become exercisable as follows:

(i)

twenty-five percent (25%) of the underlying shares on the first anniversary of the date of grant; and

(ii)

one-forty eighth (1/48) of the underlying shares monthly thereafter.

On September 1, 2011, 200,000 non-qualified stock options were granted under the 2010 Plan to non-employee directors for services to be provided to the Company, at an exercise price of $1.25 per share. These options have a ten-year contractual term and shall vest and become exercisable as follows:

(i)

80,000 option shares shall vest on September 1, 2011;

(ii)

30,000 options shares shall vest on December 1, 2011;

(iii)

30,000 options shares shall vest on March 1, 2012;

(iv)

30,000 options shares shall vest on June 1, 2012;

(v)

30,000 options shares shall vest on September 1, 2012.

On April 30, 2012, 19,757 non-qualified stock options were granted under the 2010 Plan to non-employee directors for serving as directors of the Company, at an exercise price of $6.00 per share. These options have a ten-year contractual term and shall vest and become exercisable in full immediately as of the grant date.

On December 17, 2012, 228,000 non-qualified stock options were granted under the 2010 Plan to employees as part of their employment agreements, at an exercise price of $4.24 per share. On December 20, 2012, 200,000 non-qualified stock options were granted outside of the 2010 Plan, but governed in all respects by the 2010 Plan, to an employee as part of his employment agreement, at an exercise price of $4.11 per share. These options each have a ten-year contractual term and shall vest and become exercisable as follows:

(i)

twenty-five percent (25%) of the underlying shares on the first anniversary of the date employment commence; and

(ii)

One-sixteenth (1/16) of the underlying shares quarterly thereafter.

In accordance with the guidance provided in ASC Topic 718, Stock Compensation (formerly SFAS 123R), the compensation costs associated with these options are recognized, based on the grant-date fair values of these options, over the requisite service period, or vesting period. Accordingly, the Company recognized a compensation expense of $1,011,820 and $70,662 for the six months ended June 30, 2013 and 2012, respectively.

The Company estimated the fair value of these options using the Black-Scholes-Merton option pricing model based on the following weighted-average assumptions:

							Employees &			Non-employee			Non-employee
	CEO & CSO			Dr. Hunkapiller			Officers			Directors			Directors			Employees			Employees
Date of grant	22-Jul-10			4-Apr-11			1-Sep-11			1-Sep-11			30-Apr-12			17-Dec-12			20-Dec-12
Fair value of common stock on date of grant	$	2.7560	(B)	$	0.9060	(C)	$	0.9060	(C)	$	0.9060	(C)	$	6.00	(D)	$	4.24	(E)	$	4.11	(E)
Exercise price of the options	$	5.00		$	1.25		$	1.25		$	1.25		$	6.00		$	4.24		$	4.11
Expected life of the options (years)		3.33			5.31			5.65			5.65			5.00			5.74-6.10			6.11
Dividend yield		0.00	%		0.00	%		0.00	%		0.00	%		0.00	%		0.00	%		0.00	%
Expected volatility		58.59	%		54.12	%		53.90	%		53.90	%		62.46	%		42.44-44.58	%		42.44	%
Risk-free interest rate		1.03	%		2.26	%		1.08	%		1.08	%		0.89	%		0.91-0.99	%		0.99	%
Expected forfeiture per year (%)		0.00	%		0.00	%(A)					0.00	%		0.00	%		0.00-10.00	%		0.00	%
Weighted-average fair value of the options (per unit)	$	0.6744		$	0.3729		$	0.3579		$	0.3579		$	3.0367		$	1.7426-1.7887		$	1.7842

				Employees &
	Employee			Officers			Employee			CEO & CSO
Date of grant	3-Jan-13			4-Jan-13			5-Jan-13			11-Mar-13
Fair value of common stock on date of grant	$	4.31	(E)	$	4.11	(E)	$	3.95	(E)	$	6.57	(E)
Exercise price of the options	$	4.31		$	4.11		$	3.95		$	6.57
Expected life of the options (years)		6.11			6.11			6.11			5.00
Dividend yield		0.00	%		0.00	%		0.00	%		0.00	%
Expected volatility		42.23	%		43.79	%		42.22	%		47.09	%
Risk-free interest rate		0.99	%		0.99	%		1.13	%		0.90-1.13	%
Expected forfeiture per year (%)		10.00	%		10.00	%		10.00	%		0	%
Weighted-average fair value of the options (per unit)	$	1.4712		$	1.6922		$	1.3511		$	2.7022

(A)

0.00% for the first year after the grant date, and 96.35% for every three months thereafter.

(B)

The fair value of the Company's common stock was derived implicitly from the public offering filed in March 2010 at $3.00 per share and from the terms of an underwritten offering contemplated in July 2010 at $6.00 per Unit that was filed in October 2010, with $2.756 per share being allocated to common stock using an iterative approach in order for the combined fair value of the common stock and warrants to equal the amount of consideration to be received for the offering.

(C)

The fair value of the Company's common stock was derived implicitly from the Private Placement during April through June 2011 at $1.25 per Unit, wherein one Unit was comprised of one share of common stock and one warrant to purchase one share of common stock at an exercise price of $1.60 per share.

	(D)	The fair value of the Company's common stock was derived implicitly from the public offering filed in February 2012 at $6.00 per share.

	(E)	The fair values of the Company's common stock were derived from the closing prices on the NASDAQ Capital Market as of the dates of grant.

In October 2010, the Company filed a Registration Statement on Form S-1 with the SEC. However, the market for early stage investments in medical technology transactions had deteriorated between mid-2010 and early 2011. In addition, the Company’s ability to negotiate with potential investors was limited. The Company’s cash position had also diminished since the summer of 2010 and the founders of the Company were unable to finance the Company at the level needed for growth. The withdrawal of the Registration Statement in February 2011 further weakened the impression of the Company in the market. The fair value of the Company’s common stock decreased from $2.756 in 2010 to $0.906 in 2011 primarily because the grants in 2011 relied on the arm’s-length negotiation of the private placement financing (for illiquid stock) as opposed to relying on an anticipated initial public offering (of publicly-traded stock), as was the case in 2010. The private placement transactions were between the company and over 200 accredited investors and ascribed a value of $0.906 to the Company’s common stock.

Fair value hierarchy of the above assumptions can be categorized as follows:

(1)

There were no Level 1 inputs.

(2)

Level 2 inputs include:

Risk-free rate- The risk-free rate of return reflects the interest rate for United States Treasury Note with similar time-to-maturity to that of the options.

(3)

Level 3 inputs include:

Expected lives- The expected lives of options granted were derived from the output of the option valuation model and represented the period of time that options granted are expected to be outstanding.

Expected forfeitures per year- The expected forfeitures are estimated at the dates of grant and will be revised in subsequent periods pursuant to actual forfeitures, if significantly different from the previous estimates.

Expected volatility- We did not have a historical trading history sufficient to develop an internal volatility rate for use in the model. As a result, as required by ASC 718-10-30, the Company has accounted for the options using the calculated value method. The Company identified five to seven public entities in the similar industry for which share price information was available, and considered the historical volatilities of those public entities’ share prices in calculating the expected volatility appropriate to the Company.

The estimates of fair value from the model are theoretical values of stock options and changes in the assumptions used in the model could result in materially different fair value estimates. The actual value of the stock options will depend on the market value of the Company’s common stock when the stock options are exercised.

Notwithstanding that the fair market value of the Company’s common stock in September 2011 was $0.906 per share, the Company filed a Registration Statement on Form S-1 in February 2012 to offer shares of its common stock at $5.00 to $7.00 per share. This increase in share value is justified by the accomplishments achieved by the Company between September 2011 and February 2012. Specifically, the MASCT System manufacturing had been completed, supplies for the Field Experience Trial were completed and the Company had established an FDA-compliant inventory and warehousing facility. Further, the National Reference Laboratory for Breast Health, the Company’s wholly-owned subsidiary, was established as a Delaware corporation, was equipped and staffed, and the protocols and procedures needed to be a CLIA-registered facility were put in place. Moreover, the ForeCYTE test, which involves cytopathology and five biomarkers of hyperplasia and one biomarker of sample integrity, was completed, tested, and validated to CLIA standards. Computer hardware and software was acquired, set up, made operational, and the ForeCYTE report template, with unique reporting information for the requesting physician and a patient letter template, were created. The company explored and identified a technology for the ArgusCYTE test, negotiated a supply agreement with the supplier, and tested and validated the test. An ArgusCYTE report template was also established and a new reporting scheme invented and a patent application filed.

Further, the Company negotiated the acquisition of the FullCYTE Microcatheter System from Hologics, reestablished the supply chain and began preparing for a commercial launch later in 2012 or early 2013. In doing so, the Company increased its U.S. patent portfolio from 5 to 31 and its total portfolio of patents and applications to over 120. The Hologic patent estate also contains the key patents that permit microcatheter-based intraductal treatment of cancer and pre-cancer. The Company also prepared marketing documents for the launch of the ForeCYTE and ArgusCYTE tests, which occurred in December 2011. The Company launched a clinical trial of the FullCYTE microcatheter to establish the feasibility of performing Next Generation Sequencing on the samples obtained with the microcatheter, negotiated the acquisition of the NextCYTE technology, and is conducting a study of the utility of the technology in providing superior information in the setting of cancer diagnosis and treatment selection.

The Company also established third-party relationships to perform the reimbursement billing in anticipation of the commercial launch and to permit electronic remittance of testing revenue. The Company commenced a Field Test Experience limited launch of both the ForeCYTE and ArgusCYTE tests on schedule in December 2011 and has seen significant market acceptance of both tests from the doctors and clinics using the tests. The Company passed a CLIA inspection and became CLIA-certified, has obtained several state licenses and has pending applications in all remaining states where licensure is required. Finally, the Board of Directors and scientific advisory board were each strengthened with the addition of key new executives and scientists.

The Board of Directors considered each of the foregoing achievements, and considered input from the Company’s investment bankers, in determining that the value of the Company supports a valuation of $5.00 to $7.00 per share of the Company’s common stock.

Options issued and outstanding as of June 30, 2013 and their activities during the six months then ended are as follows:

	Number of Underlying Shares		Weighted-Average Exercise Price Per Share		Weighted-Average Contractual Life Remaining in Years
Outstanding as of January 1, 2013		1,052,137	$	3.78
Granted		1,302,654		5.02
Expired		-		-
Forfeited		(12,709)		3.10
Exercised		(5,546)		1.79
Outstanding as of June 30, 2013		2,336,536		4.48		8.36
Exercisable as of June 30, 2013		870,501		4.35		6.59
Vested and expected to vest ⁽¹⁾		2,178,857		4.48		8.26

(1) includes vested shares and unvested shares after a forfeiture rate is applied.

As of June 30, 2013 and December 31, 2012, the aggregate intrinsic value of options outstanding was $3,727,412 and $1,150,416, respectively.

A summary of the status of the Company’s unvested shares as of June 30, 2013 and changes during the six month period then ended is presented below:

Unvested Shares	Shares		Weighted-Average Grant-Date Fair Value
Unvested as of January 1, 2013		520,835	$	824,549
Granted		1,302,654		2,592,353
Vested		(339,199)		(719,032)
Exercised		(5,546)		(3,370)
Forfeited		(12,709)		(15,623)
Unvested as of June 30, 2013		1,466,035	$	2,678,877

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References + Details

ASSET PURCHASE	6 Months Ended
ASSET PURCHASE	Jun. 30, 2012
Asset Purchase [Abstract]
Schedule of Asset Purchase [Text Block]	NOTE 13: ASSET PURCHASE On September 30, 2012, the Company entered into an asset purchase agreement with Acueity Healthcare, Inc (“Acueity”) to acquire substantially all of the assets of Acueity. Through the asset purchase, the Company acquired 35 issued patents (18 issued in the U.S. and 17 issued in foreign countries), 41 patent applications (32 in the U.S. and 9 in foreign countries), six 510(k) FDA marketing authorizations related to the manufacturing, use, and sale of the Viaduct Miniscope and accessories, the Manoa Breast Biopsy system, the Excisor Bioptome, the Acueity Medical Light Source, the Viaduct Microendoscope and accessories, and cash in the amount of $400,000; no liabilities were assumed in the transaction. In consideration for the assets, the Company issued 862,500 shares of common stock, valued at $5.00 per share, the offering price listed on the prospectus filed pursuant to Rule 424(b)(4) on November 9, 2012, and warrants to purchase up to 325,000 shares of common stock at an exercise price of $5.00 per share, to the shareholders of Acueity, subject to a six-month lock up agreement which has since lapsed. The warrants, which have a five-year term, do not have a cashless exercise provision. The warrants were valued at $2.3457 per warrant, using a Black-Scholes-Merton Valuation Technique because it embodies all of the requisite assumptions (including trading volatility, estimated terms and risk-free rates) necessary to determine the fair value of the warrants (see Note 8). There are no future financial obligations from the Company to Acueity from the commercialization of the acquired assets.

SUBSEQUENT EVENTS	6 Months Ended
SUBSEQUENT EVENTS	Jun. 30, 2013
Subsequent Events [Abstract]
Subsequent Events [Text Block]	NOTE 14: SUBSEQUENT EVENTS Management has evaluated subsequent events through the date of this report which is the date the consolidated financial statements were available to be issued. All subsequent events requiring recognition as of June 30, 2013 have been incorporated into these consolidated financial statements and there are no subsequent events that require disclosure in accordance with FASB ASC Topic 855, “Subsequent Events”, except as follows: From July 1, 2013 through the date of filing of this report, the Company has sold a total of 200,000 shares of Common Stock to Aspire Capital Fund LLC under the stock purchase agreement dated March 27, 2013 with aggregate gross proceeds to the Company of $930,165. On July 2013, the Company entered into an agreement with ARE LLC (Alexandria) to lease additional office spaces in our existing building under a separate lease agreement. The lease is from August 2013 through November 2014 and, the gross rent is $ 4,500 per month.

SUMMARY OF ACCOUNTING POLICIES (Policies)

6 Months Ended

Jun. 30, 2013

Accounting Policies [Abstract]

Basis of Accounting, Policy [Policy Text Block]

Basis of Presentation:

New Accounting Pronouncements, Policy [Policy Text Block]

Recently Issued Accounting Pronouncements:

Revenue Recognition, Policy [Policy Text Block]

Revenue Recognition:

Overview

Product Revenue

Service Revenue

Cash and Cash Equivalents, Policy [Policy Text Block]

Cash and Cash Equivalents:

Cash and cash equivalents include cash and all highly liquid instruments with original maturities of three months or less.

Use of Estimates, Policy [Policy Text Block]

Use of Estimates:

Trade and Other Accounts Receivable, Policy [Policy Text Block]

Accounts Receivable:

Inventory, Policy [Policy Text Block]

Inventories:

Property, Plant and Equipment, Policy [Policy Text Block]

Property, plant, and equipment:

Depreciation is computed using the straight-line method over the estimated useful lives of the assets as follows:

	Useful Life (in years)
Machinery and equipment		5
Leasehold improvements		2.083

Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]

Intangible assets:

Amortization is computed using the straight-line method over the estimated useful lives of the assets as follows:

	Useful Life (in years)
Patents		9-14
Software		3

Research and Development Expense, Policy [Policy Text Block]

Research and Development Expenses:

Research and development costs are generally expensed as incurred. The Company’s research and development expenses consist of costs incurred for internal and external research and development.

Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]

Share Based Payments:

SUMMARY OF ACCOUNTING POLICIES (Tables)

6 Months Ended

Jun. 30, 2013

Accounting Policies [Abstract]

Property, Plant and Equipment, Useful Life [Table Text Block]

Depreciation is computed using the straight-line method over the estimated useful lives of the assets as follows:

	Useful Life (in years)
Machinery and equipment		5
Leasehold improvements		2.083

Schedule of Finite-Lived Intangible Assets [Table Text Block]

Amortization is computed using the straight-line method over the estimated useful lives of the assets as follows:

	Useful Life (in years)
Patents		9-14
Software		3

PREPAID EXPENSES (Tables)

6 Months Ended

Jun. 30, 2013

Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]

Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]

Prepaid expenses consisted of the following:

	June 30, 2013		December 31, 2012
Prepaid Stock Purchase Agreement Service Fee	$	2,188,542	$	-
Prepaid Insurance		52,864		62,551
Prepaid Hardware/Software Maintenance and Support Service Fee		37,867		20,000
Prepaid Payroll Taxes		35,950		40,082
Prepaid Rent		25,629
Prepaid Tradeshow		6,849		-
	$	2,347,701	$	122,633

PROPERTY, PLANT, AND EQUIPMENT (Tables)

6 Months Ended

Jun. 30, 2013

Property, Plant and Equipment [Abstract]

Property, Plant and Equipment [Table Text Block]

Property, plant and equipment consisted of the following:

	June 30, 2013		December 31, 2012
Machinery and equipment	$	178,752	$	97,383
Leasehold Improvements		93,665		93,665
Less: Accumulated depreciation		(66,617)		(31,081)
Property, plant, and equipment, net	$	205,800	$	159,967

INTANGIBLE ASSETS (Tables)

6 Months Ended

Jun. 30, 2013

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Intangible Assets and Goodwill [Table Text Block]

Intangible assets consisted of the following:

	June 30,		December 31,
	2013		2012
Patents	$	4,704,853	$	4,704,853
Software		58,966		50,466
Less: Accumulated amortization		(306,200)		(115,095)
	$	4,457,619	$	4,640,224

Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]

Future estimated amortization expenses as of June 30, 2013 for the five succeeding years is as follows:

As of June 30,	Amounts
2013	$	382,683
2014		366,022
2015		364,681
2016		363,028
2017		363,028
Thereafter		2,618,177
	$	4,457,619

ACCRUED EXPENSES (Tables)

6 Months Ended

Jun. 30, 2013

Payables and Accruals [Abstract]

Schedule of Accrued Liabilities [Table Text Block]

Accrued expenses consisted of the following:

	June 30,		December 31,
	2013		2012
Accrued expenses	$	1,289,104	$	1,374,385
Accrued bonus payable		169,375		189,131
Accrued payroll tax liabilities		27,498		18,866
Deferred Rent		72,537		-
	$	1,558,514	$	1,582,382

STOCKHOLDERS' EQUITY (Tables)

6 Months Ended

Jun. 30, 2013

Investor, Placement Agent1 and Placement Agent2 Warrants [Member]

Schedule of Fair Value of Warrants [Table Text Block]

	Fair		April-June2011			December 2011
	Value Hierarchy Level		Investor Warrants			Placement Agent Warrants			Placement Agent Warrants

Indexed shares				5,256,800			788,520			788,520
Exercise price			$	1.60		$	1.60		$	1.25

Significant assumptions:
Stock price		3	$	0.906		$	0.906		$	0.906
Remaining term		3		6 years			6 years			6 years
Risk free rate		2		2.49	%		1.12	%		1.12	%
Expected volatility		3		53.55	%		54.21	%		54.21	%

Fair value hierarchy of the above assumptions can be categorized as follows:

(1)

There were no Level 1 inputs.

(2)

Level 2 inputs include:

Risk-free rate- The risk-free rate of return reflects the interest rate for United States Treasury Note with similar time-to-maturity to that of the warrants.

(3)

Level 3 inputs include:

Acueity Warrants [Member]

Schedule of Fair Value of Warrants [Table Text Block]

The Acueity Warrants were valued at $762,353 or $2.3457 per warrant. The following tables reflect assumptions used to determine the fair value of the Warrants:

	Fair Value Hierarchy		September 2012
	Level		Acueity Warrants

Indexed shares				325,000
Exercise price			$	5.00

Significant assumptions:
Stock price		3	$	5.00
Remaining term		3		5 years
Risk free rate		2		0.62	%
Expected volatility		3		56.54	%

Fair value hierarchy of the above assumptions can be categorized as follows:

(1)

There were no Level 1 inputs.

(2)

Level 2 inputs include:

Risk-free rate- The risk-free rate of return reflects the interest rate for United States Treasury Note with similar time-to-maturity to that of the warrants.

(3)

Level 3 inputs include:

COMMITMENTS AND CONTINGENCIES (Tables)

6 Months Ended

Jun. 30, 2013

Commitments and Contingencies Disclosure [Abstract]

Operating Leases of Lessee Disclosure [Table Text Block]

The future minimum lease payments due subsequent to June 30, 2013 under all non-cancelable operating leases for the next five years are as follows:

As of June 30,	Amount
2014	$	323,969
2015		132,737
2016		-
2017		-
2018		-
Thereafter		-
Total minimum lease payments	$	456,706

- Definition

Tabular disclosure of a lessee's leasing arrangements including: (1) the basis on which contingent rental payments are determined, (2) the existence and terms of renewal or purchase options and escalation clauses, (3) restrictions imposed by lease arrangements, such as those concerning dividends, additional debt, and further leasing, (4) rent holidays, rent concessions, or leasehold improvement incentives and unusual provisions or conditions. Disclosure may also include the specific period used to amortize material leasehold improvements made at the inception of the lease or during the lease term. Additionally, for operating leases having initial or remaining noncancelable lease terms in excess of one year: (a) future minimum rental payments required as of the date of the latest balance sheet presented, in the aggregate and for each of the five succeeding fiscal years, (b) the total of minimum rentals to be received in the future under noncancelable subleases as of the date of the latest balance sheet presented, and (c) for all operating leases, rental expense for each period for which an income statement is presented, with separate amounts for minimum rentals, contingent rentals, and sublease rentals. Rental payments under leases with terms of a month or less that were not renewed need not be included.

+ References + Details

RELATED PARTY TRANSACTIONS (Tables)

6 Months Ended

Jun. 30, 2013

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]

The Company estimated the fair value of these options using the Black-Scholes-Merton option pricing model based on the following weighted-average assumptions:

							Employees &			Non-employee			Non-employee
	CEO & CSO			Dr. Hunkapiller			Officers			Directors			Directors			Employees			Employees
Date of grant	22-Jul-10			4-Apr-11			1-Sep-11			1-Sep-11			30-Apr-12			17-Dec-12			20-Dec-12
Fair value of common stock on date of grant	$	2.7560	(B)	$	0.9060	(C)	$	0.9060	(C)	$	0.9060	(C)	$	6.00	(D)	$	4.24	(E)	$	4.11	(E)
Exercise price of the options	$	5.00		$	1.25		$	1.25		$	1.25		$	6.00		$	4.24		$	4.11
Expected life of the options (years)		3.33			5.31			5.65			5.65			5.00			5.74-6.10			6.11
Dividend yield		0.00	%		0.00	%		0.00	%		0.00	%		0.00	%		0.00	%		0.00	%
Expected volatility		58.59	%		54.12	%		53.90	%		53.90	%		62.46	%		42.44-44.58	%		42.44	%
Risk-free interest rate		1.03	%		2.26	%		1.08	%		1.08	%		0.89	%		0.91-0.99	%		0.99	%
Expected forfeiture per year (%)		0.00	%		0.00	%(A)					0.00	%		0.00	%		0.00-10.00	%		0.00	%
Weighted-average fair value of the options (per unit)	$	0.6744		$	0.3729		$	0.3579		$	0.3579		$	3.0367		$	1.7426-1.7887		$	1.7842

				Employees &
	Employee			Officers			Employee			CEO & CSO
Date of grant	3-Jan-13			4-Jan-13			5-Jan-13			11-Mar-13
Fair value of common stock on date of grant	$	4.31	(E)	$	4.11	(E)	$	3.95	(E)	$	6.57	(E)
Exercise price of the options	$	4.31		$	4.11		$	3.95		$	6.57
Expected life of the options (years)		6.11			6.11			6.11			5.00
Dividend yield		0.00	%		0.00	%		0.00	%		0.00	%
Expected volatility		42.23	%		43.79	%		42.22	%		47.09	%
Risk-free interest rate		0.99	%		0.99	%		1.13	%		0.90-1.13	%
Expected forfeiture per year (%)		10.00	%		10.00	%		10.00	%		0	%
Weighted-average fair value of the options (per unit)	$	1.4712		$	1.6922		$	1.3511		$	2.7022

(A)

0.00% for the first year after the grant date, and 96.35% for every three months thereafter.

(B)

(C)

	(D)	The fair value of the Company's common stock was derived implicitly from the public offering filed in February 2012 at $6.00 per share.

	(E)	The fair values of the Company's common stock were derived from the closing prices on the NASDAQ Capital Market as of the dates of grant.

Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]

Options issued and outstanding as of June 30, 2013 and their activities during the six months then ended are as follows:

	Number of Underlying Shares		Weighted-Average Exercise Price Per Share		Weighted-Average Contractual Life Remaining in Years
Outstanding as of January 1, 2013		1,052,137	$	3.78
Granted		1,302,654		5.02
Expired		-		-
Forfeited		(12,709)		3.10
Exercised		(5,546)		1.79
Outstanding as of June 30, 2013		2,336,536		4.48		8.36
Exercisable as of June 30, 2013		870,501		4.35		6.59
Vested and expected to vest ⁽¹⁾		2,178,857		4.48		8.26

(1) includes vested shares and unvested shares after a forfeiture rate is applied.

Schedule of Share-based Compensation Arrangement by Share-based Payment Award Non-Vested Shares [Table Text Block]

A summary of the status of the Company’s unvested shares as of June 30, 2013 and changes during the six month period then ended is presented below:

Unvested Shares	Shares		Weighted-Average Grant-Date Fair Value
Unvested as of January 1, 2013		520,835	$	824,549
Granted		1,302,654		2,592,353
Vested		(339,199)		(719,032)
Exercised		(5,546)		(3,370)
Forfeited		(12,709)		(15,623)
Unvested as of June 30, 2013		1,466,035	$	2,678,877

NATURE OF OPERATIONS (Details Textual) - USD ($)	3 Months Ended		6 Months Ended		9 Months Ended	50 Months Ended
NATURE OF OPERATIONS (Details Textual) - USD ($)	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012	Sep. 30, 2012	Jun. 30, 2013
Revenue, Net	$ 326,078	$ 223,097	$ 508,748	$ 277,810		$ 992,090
Cash Acquired from Acquisition					$ 400,000

SUMMARY OF ACCOUNTING POLICIES (Details)	6 Months Ended
SUMMARY OF ACCOUNTING POLICIES (Details)	Jun. 30, 2013
Machinery and Equipment [Member]
Property, Plant and Equipment, Useful Life	5 years
Leasehold Improvements [Member]
Property, Plant and Equipment, Useful Life	2 years 30 days

SUMMARY OF ACCOUNTING POLICIES (Details 1)	6 Months Ended
SUMMARY OF ACCOUNTING POLICIES (Details 1)	Jun. 30, 2013
Patents [Member] \| Minimum [Member]
Finite-Lived Intangible Asset, Useful Life	9 years
Patents [Member] \| Maximum [Member]
Finite-Lived Intangible Asset, Useful Life	14 years
Computer Software, Intangible Asset [Member]
Finite-Lived Intangible Asset, Useful Life	3 years

SUMMARY OF ACCOUNTING POLICIES (Details Textual) - USD ($)	6 Months Ended		12 Months Ended	50 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Dec. 31, 2012	Jun. 30, 2013
Loss on reduction of inventory to LCM	$ 20,323	$ 23,807	$ 29,884	$ 142,233

PREPAID EXPENSES (Details) - USD ($)	Jun. 30, 2013	Dec. 31, 2012
Prepaid Stock Purchase Agreement Service Fee	$ 2,188,542	$ 0
Prepaid Insurance	52,864	62,551
Prepaid Hardware/Software Maintenance and Support Service Fee	37,867	20,000
Prepaid Payroll Taxes	35,950	40,082
Prepaid Rent	25,629
Prepaid Tradeshow	6,849	0
Prepaid expense	$ 2,347,701	$ 122,633

PROPERTY, PLANT, AND EQUIPMENT (Details) - USD ($)	Jun. 30, 2013	Dec. 31, 2012
Machinery and equipment	$ 178,752	$ 97,383
Leasehold Improvements	93,665	93,665
Less: Accumulated depreciation	(66,617)	(31,081)
Property, plant, and equipment, net	$ 205,800	$ 159,967

PROPERTY, PLANT, AND EQUIPMENT (Details Textual) - USD ($)	6 Months Ended
	Jun. 30, 2013	Jun. 30, 2012
Depreciation	$ 35,537	$ 8,647

INTANGIBLE ASSETS (Details) - USD ($)	Jun. 30, 2013	Dec. 31, 2012
Patents	$ 4,704,853	$ 4,704,853
Software	58,966	50,466
Less: Accumulated amortization	(306,200)	(115,095)
Intangible assets, net	$ 4,457,619	$ 4,640,224

INTANGIBLE ASSETS (Details 1) - USD ($)	Jun. 30, 2013	Dec. 31, 2012
2013	$ 382,683
2014	366,022
2015	364,681
2016	363,028
2017	363,028
Thereafter	2,618,177
Intangible assets, net	$ 4,457,619	$ 4,640,224

INTANGIBLE ASSETS (Details Textual) - USD ($)	6 Months Ended
INTANGIBLE ASSETS (Details Textual) - USD ($)	Jun. 30, 2013	Jun. 30, 2012
Computer Software, Intangible Asset [Member]
Finite-Lived Intangible Asset, Useful Life	3 years
Amortization of Intangible Assets	$ 9,591	$ 8,410
Patents [Member]
Amortization of Intangible Assets	$ 181,514	$ 0
Patents [Member] \| Minimum [Member]
Finite-Lived Intangible Asset, Useful Life	9 years
Patents [Member] \| Maximum [Member]
Finite-Lived Intangible Asset, Useful Life	14 years

ACCRUED EXPENSES (Details) - USD ($)	Jun. 30, 2013	Dec. 31, 2012
Accrued expenses	$ 1,289,104	$ 1,374,385
Accrued bonus payable	169,375	189,131
Accrued payroll tax liabilities	27,498	18,866
Deferred Rent	72,537	0
Accrued Liabilities, Current	$ 1,558,514	$ 1,582,382

STOCKHOLDERS' EQUITY (Details 1) - $ / shares

1 Months Ended

3 Months Ended

Dec. 31, 2011

Jun. 30, 2011

Sep. 30, 2012

Dec. 30, 2011

Significant assumptions:

Stock price

$ 5.00

Placement Agent1 [Member]

Indexed shares

788,520

Exercise price

$ 1.60

Placement Agent2 [Member]

Indexed shares

788,520

Exercise price

$ 1.25

Investor Warrants [Member]

Indexed shares

5,256,800

Exercise price

$ 1.60

Fair Value, Inputs, Level 3 [Member] | Placement Agent1 [Member]

Significant assumptions:

Stock price

^[1]

0.906

Remaining term

^[2]

6 years

Expected volatility

^[3]

54.21%

Fair Value, Inputs, Level 3 [Member] | Placement Agent2 [Member]

Significant assumptions:

Stock price

^[1]

$ 0.906

Remaining term

^[2]

6 years

Expected volatility

^[3]

54.21%

Fair Value, Inputs, Level 3 [Member] | Investor Warrants [Member]

Significant assumptions:

Stock price

^[1]

$ 0.906

Remaining term

^[2]

6 years

Expected volatility

^[3]

53.55%

Fair Value, Inputs, Level 2 [Member] | Placement Agent1 [Member]

Significant assumptions:

Risk free rate

^[4]

1.12%

Fair Value, Inputs, Level 2 [Member] | Placement Agent2 [Member]

Significant assumptions:

Risk free rate

^[4]

1.12%

Fair Value, Inputs, Level 2 [Member] | Investor Warrants [Member]

Significant assumptions:

Risk free rate

^[4]

2.49%

[1]	Stock price- The Company's common stock was not publicly traded at the time the Warrants were issued. Therefore, the stock price was determined implicitly from an iterative process in order for the combined fair value of the common stock and the warrants to equal the amount of proceeds received in the Private Placement, based upon the assumption that the Private Placement was the result of an arm's length transaction.
[2]	Remaining term- The Company does not have a history to develop the expected term for its warrants. Accordingly, the Company expected that the Initial Exercise Date to occur within one year from the date of issuance plus the contractual term in the calculations.
[3]	Expected volatility- We did not have a historical trading history sufficient to develop an internal volatility rate for use in the model. As a result, as required by ASC 718-10-30, the Company has accounted for the warrants using the calculated value method. The Company identified seven public entities in the similar industry for which share price information was available, and considered the historical volatilities of those public entities' share prices in calculating the expected volatility appropriate to the Company.
[4]	Risk-free rate- The risk-free rate of return reflects the interest rate for United States Treasury Note with similar time-to-maturity to that of the warrants.

STOCKHOLDERS' EQUITY (Details 2)

9 Months Ended

Sep. 30, 2012

$ / shares

Significant assumptions:

Stock price

$ 5.00

Acueity Warrants [Member]

Indexed shares | shares

325,000

Exercise price

$ 5.00

Acueity Warrants [Member] | Fair Value, Inputs, Level 3 [Member]

Significant assumptions:

Stock price

$ 5.00

^[1]

Remaining term

5 years

^[2]

Expected volatility

56.54%

^[3]

Acueity Warrants [Member] | Fair Value, Inputs, Level 2 [Member]

Significant assumptions:

Risk free rate

0.62%

^[4]

[1]	Stock price- The Company’s common stock was not publicly traded at the time the Acueity Warrants were issued. Therefore, the stock price was determined at the offering price of the then contemplated initial public offering, for which the registration statement on Form S-1 (File No. 333-179500) was subsequently declared effective by the Securities and Exchange Commission on November 7, 2012, and a prospectus was subsequently filed pursuant to Rule 424(b)(4) on November 9, 2012 (see Note 14).
[2]	Remaining term- The Company does not have a history to develop the expected term for its warrants. Accordingly, the Company expected that the Initial Exercise Date to occur within one year from the date of issuance plus the contractual term in the calculations.
[3]	Expected volatility- We did not have a historical trading history sufficient to develop an internal volatility rate for use in the model. As a result, as required by ASC 718-10-30, the Company has accounted for the warrants using the calculated value method. The Company identified seven public entities in the similar industry for which share price information was available, and considered the historical volatilities of those public entities’ share prices in calculating the expected volatility appropriate to the Company.
[4]	Risk-free rate- The risk-free rate of return reflects the interest rate for United States Treasury Note with similar time-to-maturity to that of the warrants.

STOCKHOLDERS' EQUITY (Details Textual) - USD ($)	1 Months Ended																						3 Months Ended			6 Months Ended	9 Months Ended	12 Months Ended
STOCKHOLDERS' EQUITY (Details Textual) - USD ($)	Jun. 30, 2013	May 31, 2013	Mar. 11, 2013	Jan. 24, 2013	Jan. 05, 2013	Jan. 04, 2013	Dec. 20, 2012	Dec. 17, 2012	Nov. 07, 2012	Sep. 30, 2012	Apr. 30, 2012	Sep. 30, 2011	Sep. 01, 2011	Apr. 04, 2011	Sep. 30, 2010	Sep. 28, 2010	Apr. 27, 2010	Jan. 23, 2010	Jan. 21, 2010	Dec. 28, 2009	Jul. 28, 2009	Apr. 29, 2009	Jun. 30, 2013	Jun. 30, 2013	Jun. 30, 2011	Jun. 30, 2013	Sep. 30, 2012	Dec. 31, 2010	Jan. 31, 2013	Dec. 31, 2012	Jan. 31, 2012
Total Shares Authorized	85,000,000																						85,000,000	85,000,000		85,000,000				85,000,000
Common Stock, Shares Authorized	75,000,000																						75,000,000	75,000,000		75,000,000				75,000,000
Common Stock, Par or Stated Value Per Share (in dollars per share)	$ 0.001																						$ 0.001	$ 0.001		$ 0.001				$ 0.001
Common stock, shares issued	15,338,074																						15,338,074	15,338,074		15,338,074				12,919,367
Preferred Stock, Shares Authorized	10,000,000																						10,000,000	10,000,000		10,000,000				10,000,000
Preferred Stock, Par or Stated Value Per Share (in dollars per share)	$ 0.001																						$ 0.001	$ 0.001		$ 0.001				$ 0.001
Stockholders' Equity, Reverse Stock Split															1-for-2.26332
Stock Issued During Period, Shares, Acquisitions																											862,500
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross																										1,302,654
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price																										$ 1.79
Non-Qualified Under 2010 Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	163,000	329,944	70,710			405,000							200,000	45,000
Stock Options Under 2010 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross																							250,000
Inducement Stock Options 2010 Plans [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross							200,000
Employees Under 2010 Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross																										120,000
Stock Option and Incentive Plan 2010 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period																10 years
Common Stock, Capital Shares Reserved for Future Issuance																1,000,000													500,000		400,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross					32,000	95,000		228,000																		87,000
Private Placement [Member]
Equity Issuance, Per Share Amount																										$ 5.80
Cash Fee Equals to Percentage of Gross Proceeds from Sale of Common Stock and Warrants																									10.00%
Percentage of Non-Accountable Expense Allowance																									3.00%
Fees and Commissions, Other																									$ 857,230
Initial Fair Value of Warrants																									$ 495,876
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross																							18,000
Class of Warrant or Right, Date from which Warrants or Rights Exercisable																										May 15, 2017
Fair Value Adjustment of Warrants																										$ 26,053
IPO [Member]
Stock Issued During Period, Shares, New Issues									800,000
Common Stock Offering Price									$ 5.00
Proceeds from Issuance Initial Public Offering									$ 3,454,000
Underwriting Commission and Discount									$ 546,000
Securities Purchase Agreements, Investor Warrants [Member]
Sale of Stock, Number of Shares Issued in Transaction																									5,256,800
Sale of Stock, Price Per Share	$ 1.25																						$ 1.25	$ 1.25	$ 1.25	$ 1.25
Class of Warrant or Right, Number of Securities Called by Warrants or Rights																									5,256,800
Proceeds from Issuance of Private Placement																									$ 6,571,000
Placement Agent Additional Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights																									788,520
Exercise Price of Common Stock																									$ 1.25
Placement Agent1 [Member]
Warrants and Rights Outstanding	$ 228,712																						$ 228,712	$ 228,712		$ 228,712
Fair Value of Warrants (in dollars per warrant)	$ 0.290																						$ 0.290	$ 0.290		$ 0.290
Placement Agent Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights																									788,520
Exercise Price of Common Stock																									$ 1.60
Placement Agent2 [Member]
Warrants and Rights Outstanding	$ 267,164																						$ 267,164	$ 267,164		$ 267,164
Fair Value of Warrants (in dollars per warrant)	$ 0.339																						$ 0.339	$ 0.339		$ 0.339
Acueity Warrants [Member]
Stock Issued During Period, Shares, Acquisitions																											862,500
Class of Warrant or Right, Number of Securities Called by Warrants or Rights										325,000																	325,000
Warrants and Rights Outstanding										$ 762,353																	$ 762,353
Fair Value of Warrants (in dollars per warrant)										$ 2.3457																	$ 2.3457
Private Placement to Accredited Investors [Member]
Common stock, shares issued	1,279,642																						1,279,642	1,279,642		1,279,642
Stock Issued During Period Shares Issued For Exercise Of Warrants																										60,000
Prior to Reverse Share Split on September 28, 2010 [Member] \| Stock Option and Incentive Plan 2010 [Member]
Common Stock, Capital Shares Reserved for Future Issuance																2,263,320
Chief Executive Officer [Member]
Stock Issued During Period, Shares, Issued for Cash																						883,662
Stock Issued During Period, Value, Issued for Cash																						$ 12,000
Equity Issuance, Per Share Amount																						$ 0.014
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross																												250,000
Chief Executive Officer [Member] \| Prior to Reverse Share Split on September 28, 2010 [Member]
Stock Issued During Period, Shares, Issued for Cash																						2,000,000
Equity Issuance, Per Share Amount																						$ 0.006
Director [Member]
Stock Issued During Period, Shares, Issued for Cash																					39,765
Stock Issued During Period, Value, Issued for Cash																					$ 540
Equity Issuance, Per Share Amount																					$ 0.014
Director [Member] \| Prior to Reverse Share Split on September 28, 2010 [Member]
Stock Issued During Period, Shares, Issued for Cash																					90,000
Equity Issuance, Per Share Amount																					$ 0.006
Member of Board of Directors [Member] \| Non-Qualified Under 2010 Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross											19,757
Various Employees [Member]
Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures																										5,546
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price																										$ 1.25
Proceeds from Stock Options Exercised																										$ 6,000
Ensisheim Partners Llc [Member]
Stock Issued During Period, Shares, Issued for Cash																				883,658		1,767,316
Stock Issued During Period, Value, Issued for Cash																				$ 100,000		$ 24,000
Equity Issuance, Per Share Amount																				$ 0.11		$ 0.014
Ensisheim Partners Llc [Member] \| Prior to Reverse Share Split on September 28, 2010 [Member]
Stock Issued During Period, Shares, Issued for Cash																				2,000,000		4,000,000
Equity Issuance, Per Share Amount																				$ 0.05		$ 0.006
Manistee Ventures Llc [Member]
Stock Issued During Period, Shares, Issued for Cash																						1,325,487
Stock Issued During Period, Value, Issued for Cash																						$ 18,000
Equity Issuance, Per Share Amount																						$ 0.014
Manistee Ventures Llc [Member] \| Prior to Reverse Share Split on September 28, 2010 [Member]
Stock Issued During Period, Shares, Issued for Cash																						3,000,000
Equity Issuance, Per Share Amount																						$ 0.006
Investors (44) [Member]
Stock Issued During Period, Shares, Issued for Cash																			866,007
Stock Issued During Period, Value, Issued for Cash																			$ 98,000
Equity Issuance, Per Share Amount																			$ 0.11
Investors (44) [Member] \| Prior to Reverse Share Split on September 28, 2010 [Member]
Stock Issued During Period, Shares, Issued for Cash																			1,960,000
Equity Issuance, Per Share Amount																			$ 0.05
Servicer [Member]
Stock Issued During Period, Shares, Issued for Cash																			866,007
Stock Issued During Period, Shares, New Issues																			132,549
Stock Issued During Period, Value, New Issues																			$ 15,000
Equity Issuance, Per Share Amount																			$ 0.11
Servicer [Member] \| Prior to Reverse Share Split on September 28, 2010 [Member]
Stock Issued During Period, Shares, Issued for Cash																			1,960,000
Stock Issued During Period, Shares, New Issues																			300,000
Additional Stock Issued During Period Shares Issued For Cash																			30,000
Equity Issuance, Per Share Amount																			$ 0.05
Shareholder [Member]
Stock Issued During Period, Shares, Issued for Cash																			866,007
Stock Issued During Period, Shares, New Issues																			13,255
Stock Issued During Period, Shares, Issued for Services																			53,020
Stock Issued During Period, Value, Issued for Services																			$ 6,000
Equity Issuance, Per Share Amount																			$ 0.11
Shareholder [Member] \| Prior to Reverse Share Split on September 28, 2010 [Member]
Stock Issued During Period, Shares, Issued for Cash																			1,960,000
Stock Issued During Period, Shares, New Issues																			30,000
Stock Issued During Period, Shares, Issued for Services																			120,000
Equity Issuance, Per Share Amount																			$ 0.05
Investor [Member]
Stock Issued During Period, Shares, Issued for Cash																		35,346
Stock Issued During Period, Value, Issued for Cash																		$ 4,000
Equity Issuance, Per Share Amount																		$ 0.11
Warrants and Rights Outstanding	$ 1,808,025																						$ 1,808,025	$ 1,808,025		$ 1,808,025
Fair Value of Warrants (in dollars per warrant)	$ 0.344																						$ 0.344	$ 0.344		$ 0.344
Investor [Member] \| Prior to Reverse Share Split on September 28, 2010 [Member]
Stock Issued During Period, Shares, Issued for Cash																		80,000
Equity Issuance, Per Share Amount																		$ 0.05
Website Development Services [Member]
Stock Issued During Period, Shares, Issued for Services																	13,256
Stock Issued During Period, Value, Issued for Services																	$ 50,000
Website Development Services [Member] \| Prior to Reverse Share Split on September 28, 2010 [Member]
Stock Issued During Period, Shares, Issued for Services																	30,000
Shareholders of Acueity [Member]
Stock Issued During Period, Value, New Issues										$ 4,312,500
Stock Issued During Period, Shares, Acquisitions										862,500
Employees and Officers [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross												219,000
Aspire Capital Fund, Llc [Member]
Stock Issued During Period, Shares, Issued for Cash																								600,000		933,333
Stock Issued During Period, Shares, Acquisitions																								0
Equity Issuance, Per Share Amount																								$ 5.28		$ 5.28
Fees and Commissions, Other																										$ 119,071
Proceeds from Issuance of Common Stock																								$ 2,969,740		$ 3,969,740
Aspire Capital Fund, Llc [Member] \| Chief Executive Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross																												18,000
Vendors [Member]
Stock Issued During Period, Shares, Issued for Services				32,186
Stock Issued During Period, Value, Issued for Services				$ 143,550
Equity Issuance, Per Share Amount				$ 4.46

CONCENTRATION OF CREDIT RISK (Details Textual) - USD ($)	Jun. 30, 2013	Dec. 31, 2012
Cash, FDIC Insured Amount	$ 250,000
Cash, Uninsured Amount	$ 2,189,512	$ 1,475,197

COMMITMENTS AND CONTINGENCIES (Details)	Jun. 30, 2013 USD ($)
2014	$ 323,969
2015	132,737
2016	0
2017	0
2018	0
Thereafter	0
Total minimum lease payments	$ 456,706

COMMITMENTS AND CONTINGENCIES (Details Textual) - USD ($)	1 Months Ended					6 Months Ended		12 Months Ended
	Dec. 09, 2011	Sep. 27, 2011	Jul. 09, 2011	Mar. 04, 2011	Sep. 29, 2010	Jun. 30, 2013	Mar. 31, 2012	Dec. 31, 2012	Jun. 30, 2011
Security Deposit						$ 36,446		$ 36,447
Robert Kelly [Member]
Loss Contingency, Damages Sought, Value									$ 450,000
Lease Agreement 2010 [Member] \| Complegen Inc [Member]
Monthly Lease Rent					$ 3,658
Security Deposit					$ 3,658
Enhanced Lease Rent								4,267
Operating Leases, Rent Expense								$ 46,529
Lease Expiration Date, Description								The lease terms are from September 29, 2010 through March 31, 2011, at which time the lease has converted to month to month unless two months' prior written notice of the intent to terminate the agreement is given.
Lease Agreement March 2011 [Member] \| Sanders Properties, Llc [Member]
Monthly Lease Rent				$ 1,100
Security Deposit				$ 1,500
Operating Leases, Rent Expense						6,600
Lease Expiration Date				Mar. 31, 2014
Lease Agreement July 2011 [Member] \| Sanders Properties, Llc [Member]
Monthly Lease Rent			$ 600
Security Deposit			$ 1,200
Operating Leases, Rent Expense								$ 4,200
Lease Expiration Date			Jul. 31, 2012
Lease Agreement September 2011 [Member] \| Sanders Properties, Llc [Member]
Monthly Lease Rent		$ 1,400
Security Deposit		$ 1,000
Operating Leases, Rent Expense							$ 8,400
Lease Expiration Date		Mar. 31, 2012
Lease Agreement December 2011 [Member] \| Fred Hutchinson Research Center [Member]
Security Deposit	$ 32,789
Operating Leases, Rent Expense						$ 132,284
Lease Agreement December 2011 [Member] \| Fred Hutchinson Research Center [Member] \| Monthly Rent For Period From February 24, 2012 To August 31, 2012 [Member]
Monthly Lease Rent	16,395
Lease Agreement December 2011 [Member] \| Fred Hutchinson Research Center [Member] \| Monthly Rent For Period From September 1, 2012 To August 31, 2013 [Member]
Monthly Lease Rent	19,923
Lease Agreement December 2011 [Member] \| Fred Hutchinson Research Center [Member] \| Monthly Rent For Period From September 1, 2013 To November 29, 2014 [Member]
Monthly Lease Rent	$ 20,548

RELATED PARTY TRANSACTIONS (Details)

1 Months Ended

6 Months Ended

12 Months Ended

37 Months Ended

Oct. 31, 2010

$ / shares

Jan. 31, 2010

$ / shares

Jun. 30, 2013

Unit

$ / shares

Dec. 31, 2011

$ / shares

Mar. 31, 2013

$ / shares

Feb. 29, 2012

$ / shares

Date of grant

Sep. 01, 2011

Chief Executive Officer and Chief Scientific Officer [Member]

Fair value of common stock on date of grant

$ 2.756

$ 3.00

Chief Executive Officer and Chief Scientific Officer [Member] | Stock Option One [Member]

Date of grant

Jul. 22, 2010

Fair value of common stock on date of grant

^[1]

$ 2.7560

Exercise price of the options

$ 5.00

Expected life of the options (years)

3 years 3 months 29 days

Dividend yield

0.00%

Expected volatility

58.59%

Risk-free interest rate

1.03%

Expected forfeiture per year (%)

0.00%

Weighted-average fair value of the options (per unit) | Unit

0.6744

Chief Executive Officer and Chief Scientific Officer [Member] | Stock Option Two [Member]

Date of grant

Mar. 11, 2013

Fair value of common stock on date of grant

^[2]

$ 6.57

Exercise price of the options

$ 6.57

Expected life of the options (years)

5 years

Dividend yield

0.00%

Expected volatility

47.09%

Expected forfeiture per year (%)

0.00%

Weighted-average fair value of the options (per unit) | Unit

2.7022

Chief Executive Officer and Chief Scientific Officer [Member] | Stock Option Two [Member] | Minimum [Member]

Risk-free interest rate

0.90%

Chief Executive Officer and Chief Scientific Officer [Member] | Stock Option Two [Member] | Maximum [Member]

Exercise price of the options

$ 7.00

Risk-free interest rate

1.13%

Employees and Officers [Member] | Stock Option One [Member]

Date of grant

Sep. 01, 2011

Fair value of common stock on date of grant

^[3]

$ 0.9060

Exercise price of the options

$ 1.25

Expected life of the options (years)

5 years 7 months 24 days

Dividend yield

0.00%

Expected volatility

53.90%

Risk-free interest rate

1.08%

Weighted-average fair value of the options (per unit) | Unit

0.3579

Employees and Officers [Member] | Stock Option Two [Member]

Date of grant

Jan. 04, 2013

Fair value of common stock on date of grant

^[2]

$ 4.11

Exercise price of the options

$ 4.11

Expected life of the options (years)

6 years 1 month 10 days

Dividend yield

0.00%

Expected volatility

43.79%

Risk-free interest rate

0.99%

Expected forfeiture per year (%)

10.00%

Weighted-average fair value of the options (per unit) | Unit

1.6922

Employees [Member] | Stock Option One [Member]

Date of grant

Dec. 17, 2012

Fair value of common stock on date of grant

^[2]

$ 4.24

Exercise price of the options

$ 4.24

Dividend yield

0.00%

Employees [Member] | Stock Option One [Member] | Minimum [Member]

Expected life of the options (years)

5 years 8 months 26 days

Expected volatility

42.44%

Risk-free interest rate

0.91%

Expected forfeiture per year (%)

0.00%

Weighted-average fair value of the options (per unit) | Unit

1.7426

Employees [Member] | Stock Option One [Member] | Maximum [Member]

Expected life of the options (years)

6 years 1 month 6 days

Expected volatility

44.58%

Risk-free interest rate

0.99%

Expected forfeiture per year (%)

10.00%

Weighted-average fair value of the options (per unit) | Unit

1.7887

Employees [Member] | Stock Option Two [Member]

Date of grant

Dec. 20, 2012

Fair value of common stock on date of grant

^[2]

$ 4.11

Exercise price of the options

$ 4.11

Expected life of the options (years)

6 years 1 month 10 days

Dividend yield

0.00%

Expected volatility

42.44%

Risk-free interest rate

0.99%

Expected forfeiture per year (%)

0.00%

Weighted-average fair value of the options (per unit) | Unit

1.7842

Employees [Member] | Stock Option Three [Member]

Date of grant

Jan. 03, 2013

Fair value of common stock on date of grant

^[2]

$ 4.31

Exercise price of the options

$ 4.31

Expected life of the options (years)

6 years 1 month 10 days

Dividend yield

0.00%

Expected volatility

42.23%

Risk-free interest rate

0.99%

Expected forfeiture per year (%)

10.00%

Weighted-average fair value of the options (per unit) | Unit

1.4712

Employees [Member] | Stock Option Four [Member]

Date of grant

Jan. 05, 2013

Fair value of common stock on date of grant

^[2]

$ 3.95

Exercise price of the options

$ 3.95

Expected life of the options (years)

6 years 1 month 10 days

Dividend yield

0.00%

Expected volatility

42.22%

Risk-free interest rate

1.13%

Expected forfeiture per year (%)

10.00%

Weighted-average fair value of the options (per unit) | Unit

1.3511

Non Employee Director [Member] | Stock Option One [Member]

Date of grant

Sep. 01, 2011

Fair value of common stock on date of grant

^[3]

$ 0.9060

Exercise price of the options

$ 1.25

$ 6.00

Expected life of the options (years)

5 years 7 months 24 days

Dividend yield

0.00%

Expected volatility

53.90%

Risk-free interest rate

1.08%

Expected forfeiture per year (%)

0.00%

Weighted-average fair value of the options (per unit) | Unit

0.3579

Non Employee Director [Member] | Stock Option Two [Member]

Date of grant

Apr. 30, 2012

Fair value of common stock on date of grant

^[4]

$ 6.00

Exercise price of the options

$ 6.00

Expected life of the options (years)

5 years

Dividend yield

0.00%

Expected volatility

62.46%

Risk-free interest rate

0.89%

Expected forfeiture per year (%)

0.00%

Weighted-average fair value of the options (per unit) | Unit

3.0367

Dr.Hunkapiller [Member]

Fair value of common stock on date of grant

$ 0.906

Dr.Hunkapiller [Member] | Stock Option One [Member]

Date of grant

Apr. 04, 2011

Fair value of common stock on date of grant

$ 0.9060

Exercise price of the options

$ 1.25

Expected life of the options (years)

5 years 3 months 22 days

Dividend yield

0.00%

Expected volatility

54.12%

Risk-free interest rate

2.26%

Expected forfeiture per year (%)

^[5]

0.00%

Weighted-average fair value of the options (per unit) | Unit

0.3729

[1]	The fair value of the Company's common stock was derived implicitly from the public offering filed in March 2010 at $3.00 per share and from the terms of an underwritten offering contemplated in July 2010 at $6.00 per Unit that was filed in October 2010, with $2.756 per share being allocated to common stock using an iterative approach in order for the combined fair value of the common stock and warrants to equal the amount of consideration to be received for the offering.
[2]	The fair values of the Company's common stock were derived from the closing prices on the NASDAQ Capital Market as of the dates of grant.
[3]	The fair value of the Company's common stock was derived implicitly from the Private Placement during April through June 2011 at $1.25 per Unit, wherein one Unit was comprised of one share of common stock and one warrant to purchase one share of common stock at an exercise price of $1.60 per share.
[4]	The fair value of the Company's common stock was derived implicitly from the public offering filed in February 2012 at $6.00 per share.
[5]	0.00% for the first year after the grant date, and 96.35% for every three months thereafter.

RELATED PARTY TRANSACTIONS (Details 1) - $ / shares

6 Months Ended

Jun. 30, 2013

Number of Underlying Shares, Outstanding as of January 1, 2013 (in shares)

1,052,137

Number of Underlying Shares, Granted (in shares)

1,302,654

Number of Underlying Shares, Expired (in shares)

Number of Underlying Shares, Forfeited (in shares)

(12,709)

Number of Underlying Shares, Exercised (in shares)

(5,546)

Number of Underlying Shares, Outstanding as of June 30, 2013 (in shares)

2,336,536

Number of Underlying Shares, Exercisable as of June 30, 2013 (in shares)

870,501

Number of Underlying Shares, Vested and expected to vest (in shares)

^[1]

2,178,857

Weighted-Average Exercise Price Per Share, Outstanding as of January 1, 2013 (in dollars per share)

$ 3.78

Weighted-Average Exercise Price Per Share, Granted (in dollars per share)

5.02

Weighted-Average Exercise Price Per Share, Expired (in dollars per share)

Weighted-Average Exercise Price Per Share, Forfeited (in dollars per share)

3.10

Weighted-Average Exercise Price Per Share, Exercised (in dollars per share)

1.79

Weighted-Average Exercise Price Per Share, Outstanding as of June 30, 2013 (in dollars per share)

4.48

Weighted-Average Exercise Price Per Share, Exercisable as of June 30, 2013 (in dollars per share)

4.35

Weighted-Average Exercise Price Per Share, Vested and expected to vest (in dollars per share)

$ 4.48

Weighted-Average Contractual Life Remaining in Years, Outstanding as of June 30, 2013

8 years 4 months 10 days

Weighted-Average Contractual Life Remaining in Years, Exercisable as of June 30, 2013

6 years 7 months 2 days

Weighted-Average Contractual Life Remaining in Years, Vested and expected to vest

^[1]

8 years 3 months 4 days

[1]	includes vested shares and unvested shares after a forfeiture rate is applied.

RELATED PARTY TRANSACTIONS (Details 2) $ in Thousands	6 Months Ended
RELATED PARTY TRANSACTIONS (Details 2) $ in Thousands	Jun. 30, 2013 USD ($) shares
Shares, Unvested as of January 1, 2013 (in shares) \| shares	520,835
Shares, Granted (in shares) \| shares	1,302,654
Shares, Vested (in shares) \| shares	(339,199)
Shares, Exercised (in shares) \| shares	(5,546)
Shares, Forfeited (in shares) \| shares	(12,709)
Shares, Unvested as of June 30, 2013 (in shares) \| shares	1,466,035
Weighted-Average Grant-Date Fair Value, Unvested as of January 1, 2013 (in dollars) \| $	$ 824,549
Weighted-Average Grant-Date Fair Value, Granted (in dollars) \| $	2,592,353
Weighted-Average Grant-Date Fair Value, Vested (in dollars) \| $	(719,032)
Weighted-Average Grant-Date Fair Value, Exercised (in dollars) \| $	(3,370)
Weighted-Average Grant-Date Fair Value, Forfeited (in dollars) \| $	(15,623)
Weighted-Average Grant-Date Fair Value, Unvested as of June 30, 2013 (in dollars) \| $	$ 2,678,877

RELATED PARTY TRANSACTIONS (Details Textual) - USD ($)

1 Months Ended

3 Months Ended

6 Months Ended

8 Months Ended

12 Months Ended

20 Months Ended

37 Months Ended

50 Months Ended

Oct. 11, 2012

Feb. 29, 2012

Oct. 31, 2010

Jan. 31, 2010

May 31, 2011

Mar. 31, 2011

Jun. 30, 2010

Jun. 30, 2013

Jun. 30, 2012

Jun. 30, 2010

Dec. 31, 2009

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2010

Dec. 31, 2009

Dec. 31, 2010

Mar. 31, 2013

Jun. 30, 2013

Jul. 30, 2012

Jun. 30, 2011

May 19, 2011

May 16, 2011

Nov. 03, 2010

May 26, 2009

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

1,302,654

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number

2,336,536

1,052,137

2,336,536

Share-based Compensation

$ 1,011,820

$ 70,662

$ 1,304,084

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price

$ 5.02

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value

$ 3,727,412

$ 1,150,416

$ 3,727,412

Investor Warrants [Member]

Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Exercise Price

$ 1.60

Minimum [Member]

Offer Price Per Share

$ 5.00

Maximum [Member]

Offer Price Per Share

7.00

Ensisheim Partners Llc [Member]

Exclusive License Agreement, Royalty Percentage

2.00%

Exclusive License Agreement, Minimum Royalty

$ 12,500

Exclusive License Agreement, Minimum Royalty Increased

25,000

Patents Expenses

$ 16,250

Royalty Expense

$ 12,500

Operating Lease Annual Rent

$ 13,200

Operating Leases, Rent Expense

$ 6,600

248

Security Deposit Related to Lease

$ 1,100

Security Deposit Refund

$ 1,100

Robert L.Kelly [Member]

Consulting Expense

$ 30,000

Dr.Hunkapiller [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value

$ 0.906

Dr.Hunkapiller [Member] | Stock Option One [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value

$ 0.9060

Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Exercise Price

$ 1.25

Dr.Hunkapiller [Member] | Stock Option and Incentive Plan 2010 [Member]

Modified Annual Base Salary

$ 45,000

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights

(i) 11,250 option shares shall vest ninety (90) days after the date of grant; (ii) 11,000 option shares shall vest one hundred and eighty (180) days after the date of grant; (iii) 11,500 option shares shall vest two hundred and seventy (270) days after the date of grant; (iv) 11,250 option shares shall vest three hundred and sixty (360) days after the date of grant.

Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term

10 years

Subsequent Event [Member]

Operating Leases, Rent Expense

$ 4,500

Board Of Directors Chairman and Chief Executive Office [Member]

Debt Instrument, Interest Rate, Stated Percentage

10.00%

Line of Credit Facility, Maximum Borrowing Capacity

$ 500,000

Line of Credit Facility, Interest Rate During Period

12.00%

Line of Credit Facility, Current Borrowing Capacity

$ 140,000

$ 79,300

Line of Credit Facility, Accrued Interest

$ 1,440

6,093

Line of Credit Facility, Periodic Payment, Principal

$ 79,300

5,078

Board Of Directors Chairman and Chief Executive Office [Member] | Promissory Note One [Member]

Short-term Debt

$ 5,000

Debt Instrument, Interest Rate, Stated Percentage

10.00%

Debt Instrument, Maturity Date

Dec. 31, 2010

Interest Payable, Current

$ 439

Board Of Directors Chairman and Chief Executive Office [Member] | Promissory Note Two [Member]

Debt Instrument, Interest Rate, Stated Percentage

10.00%

Interest Payable, Current

$ 8,959

Debt Instrument, Face Amount

$ 100,000

Loan Processing Fee

$ 4,000

4,000

Chief Executive Officer [Member]

Annual Base Salary

360,000

Salaries and Bonus

322,590

Modified Annual Base Salary

$ 250,000

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

250,000

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights

25% (or 62,500 shares) vested on December 31, 2010 with the remaining 75% (or 187,500 shares) to vest in equal quarterly installments over the next three years so long as the executive remains employed with the company.

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number

62,500

Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Outstanding Number

187,500

Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term

5 years

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price

$ 5.00

Chief Executive Officer [Member] | Prior to Reverse Stock Split [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

565,830

Chief Executive Officer [Member] | Research and Development Expense [Member]

Salaries and Bonus

161,295

Former President [Member]

Annual Base Salary

$ 350,000

Chief Scientific Officer [Member]

Annual Base Salary

250,000

Salaries and Bonus

243,554

Modified Annual Base Salary

$ 200,000

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

100,000

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights

25% (or 25,000 shares) vested on December 31, 2010 with the remaining 75% (or 75,000 shares) to vest in equal quarterly installments over the next three years so long as the executive remains employed with the company.

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number

25,000

Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Outstanding Number

75,000

Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term

5 years

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price

$ 5.00

Chief Scientific Officer [Member] | Prior to Reverse Stock Split [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

226,332

Chief Scientific Officer [Member] | Research and Development Expense [Member]

Salaries and Bonus

$ 243,554

Chief Executive Officer and Chief Scientific Officer [Member]

Salaries and Bonus

$ 693,048

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value

$ 2.756

$ 3.00

Chief Executive Officer and Chief Scientific Officer [Member] | Stock Option One [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value

^[1]

$ 2.7560

Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Exercise Price

5.00

Chief Executive Officer and Chief Scientific Officer [Member] | Stock Option Two [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value

^[2]

6.57

Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Exercise Price

6.57

Chief Executive Officer and Chief Scientific Officer [Member] | Stock Option Two [Member] | Maximum [Member]

Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Exercise Price

7.00

Chief Executive Officer and Chief Scientific Officer [Member] | Research and Development Expense [Member]

Salaries and Bonus

$ 492,095

Employees and Officers [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions Expected Forfeiture Rate, Description

0.00% for the first year after the grant date, and 96.35% for every three months thereafter.

Employees and Officers [Member] | Stock Option One [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value

^[3]

0.9060

Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Exercise Price

1.25

Employees and Officers [Member] | Stock Option Two [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value

^[2]

4.11

Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Exercise Price

$ 4.11

4.11

Employees and Officers [Member] | Stock Option and Incentive Plan 2010 [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

219,000

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights

(i) twenty-five percent (25%) of the underlying shares on the first anniversary of the date of grant; and (ii) one-forty eighth (1/48) of the underlying shares monthly thereafter.

Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term

10 years

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price

$ 1.25

Employees and Officers [Member] | Non-Qualified Stock Options Were Granted Under The 2010 Plan [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

228,000

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights

(i) twenty-five percent (25%) of the underlying shares on the first anniversary of the date employment commence; and (ii) One-sixteenth (1/16) of the underlying shares quarterly thereafter.

Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term

10 years

Share-based Compensation

$ 1,011,820

$ 70,662

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price

$ 4.24

Employees and Officers [Member] | Non Qualified Stock Options Were Granted Outside Of 2010 Plan [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

200,000

Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term

10 years

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price

$ 4.11

Non-Employee Director [Member] | Stock Option One [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value

^[3]

$ 0.9060

Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Exercise Price

$ 6.00

1.25

Non-Employee Director [Member] | Stock Option Two [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value

^[4]

6.00

Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Exercise Price

$ 6.00

Non-Employee Director [Member] | Stock Option and Incentive Plan 2010 [Member] | Stock Option One [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

200,000

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights

(i) 80,000 option shares shall vest on September 1, 2011; (ii) 30,000 options shares shall vest on December 1, 2011; (iii) 30,000 options shares shall vest on March 1, 2012; (iv) 30,000 options shares shall vest on June 1, 2012; (v) 30,000 options shares shall vest on September 1, 2012.

Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term

10 years

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price

$ 1.25

Non-Employee Director [Member] | Stock Option and Incentive Plan 2010 [Member] | Stock Option Two [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

19,757

Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term

10 years

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price

$ 6.00

[1]	The fair value of the Company's common stock was derived implicitly from the public offering filed in March 2010 at $3.00 per share and from the terms of an underwritten offering contemplated in July 2010 at $6.00 per Unit that was filed in October 2010, with $2.756 per share being allocated to common stock using an iterative approach in order for the combined fair value of the common stock and warrants to equal the amount of consideration to be received for the offering.
[2]	The fair values of the Company's common stock were derived from the closing prices on the NASDAQ Capital Market as of the dates of grant.
[3]	The fair value of the Company's common stock was derived implicitly from the Private Placement during April through June 2011 at $1.25 per Unit, wherein one Unit was comprised of one share of common stock and one warrant to purchase one share of common stock at an exercise price of $1.60 per share.
[4]	The fair value of the Company's common stock was derived implicitly from the public offering filed in February 2012 at $6.00 per share.

ASSET PURCHASE (Details Textual)	9 Months Ended
ASSET PURCHASE (Details Textual)	Sep. 30, 2012 USD ($) $ / shares shares
Cash Acquired from Acquisition \| $	$ 400,000
Stock Issued During Period, Shares, Acquisitions \| shares	862,500
Share Price	$ 5.00
Warrants Issued During Period Acquisitions \| shares	325,000
Warrants Exercise Price	$ 5.00
Warrant Terms	5 years
Warrant Price	$ 2.3457

SUBSEQUENT EVENTS (Details Textual) - Subsequent Event [Member]	6 Months Ended
	Jun. 30, 2013 USD ($) shares
Operating Leases, Rent Expense	$ 4,500
Lessee Leasing Arrangement Operating Leases Term of Contract	The lease is from August 2013 through November 2014
Aspire Capital Fund, Llc [Member]
Stock Issued During Period, Shares, New Issues \| shares	200,000
Stock Issued During Period, Value, New Issues	$ 930,165